
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Section 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

For the month of August 2018

Commission File No. 001-38403

CRONOS GROUP INC.

(Name of registrant)

720 King Street W., Suite 320

Toronto, Ontario

M5V 2T3

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes No

EXHIBIT INDEX

Exhibit	Description
99.1	<u>Unaudited Condensed Interim Consolidated Financial Statements dated August 13, 2018</u>
99.2	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations dated August 13, 2018</u>
99.3	<u>Form 52-109F2 – Certification of Interim Filings Full Certificate – Chief Executive Officer dated August 14, 2018</u>
99.4	<u>Form 52-109F2 – Certification of Interim Filings Full Certificate – Chief Financial Officer dated August 14, 2018</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

CRONOS GROUP INC.
(Registrant)

By: /s/ Michael Gorenstein
Name: Michael Gorenstein
Title: President and Chief Executive Officer

Date: August 14, 2018



CRONOS GROUP INC.

Unaudited Condensed Interim Consolidated Financial Statements

For the Three and Six Months Ended June 30, 2018 and June 30, 2017

(in thousands of Canadian dollars)

Cronos Group Inc.
Unaudited Condensed Interim Consolidated Financial Statements
For the three and six months ended June 30, 2018 and June 30, 2017

Table of Contents

Unaudited Condensed Interim Consolidated Statements of Financial Position	1
Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Loss	2
Unaudited Condensed Interim Consolidated Statements of Changes in Equity	3
Unaudited Condensed Interim Consolidated Statements of Cash Flows	4
Notes to Unaudited Condensed Interim Consolidated Financial Statements	5

Cronos Group Inc.
Unaudited Condensed Interim Consolidated Statements of Financial Position
As at June 30, 2018 and December 31, 2017
(in thousands of CDN \$)

	Notes	As at June 30, 2018	As at December 31, 2017
Assets			
Current assets			
Cash		\$ 89,609	\$ 9,208
Accounts receivable	22(i)	2,844	1,140
Sales taxes receivable		6,952	3,114
Prepays and other receivables		4,112	790
Biological assets	6	6,899	3,722
Inventory	6	12,334	8,416
Loan receivable	7,22(i)	314	314
Total current assets		<u>123,064</u>	<u>26,704</u>
Promissory note receivable	8,22(i)	1,304	-
Investment in Whistler	9	3,851	3,807
Other investments	10	725	1,347
Property, plant and equipment	11	93,657	56,172
Intangible assets	12	11,043	11,207
Goodwill	13	1,792	1,792
Total assets		<u>\$ 235,436</u>	<u>\$ 101,029</u>
Liabilities			
Current liabilities			
Accounts payable and other liabilities	22(ii)	<u>2,333</u>	<u>7,878</u>
Total current liabilities		2,333	7,878
Construction loan payable	14	5,565	5,367
Deferred income tax liability	21	268	1,416
Total liabilities		<u>8,166</u>	<u>14,661</u>
Shareholders' equity			
Share capital	15(a)	224,742	83,559
Shares to be issued	15(c)	17	-
Warrants	16(a)	1,868	3,364
Stock options	16(b)	3,810	2,289
Accumulated deficit		(4,051)	(3,724)
Accumulated other comprehensive income		884	880
Total shareholders' equity		<u>227,270</u>	<u>86,368</u>
Total liabilities and shareholders' equity		<u>\$ 235,436</u>	<u>\$ 101,029</u>
Commitments and contingencies	20		
Subsequent events	25		

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

Approved on behalf of the Board of Directors:

"Michael Gorenstein"
Director

"James Rudyk"
Director

Cronos Group Inc.**Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss)****For the three and six months ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except share and per share amounts)*

	Notes	Three Months Ended June 30,		Six Months Ended June 30,	
		2018	2017	2018	2017
Revenue	17	\$ 3,394	\$ 643	\$ 6,339	\$ 1,157
Cost of sales					
Inventory expensed to cost of sales, before fair value adjustments	5,6	1,254	215	2,821	413
Gross profit before fair value adjustments		2,140	428	3,518	744
Fair value adjustments					
Unrealized change in fair value of biological assets	5,6	(6,831)	(1,122)	(9,575)	(2,701)
Realized fair value adjustments on inventory sold in the period	5,6	2,625	429	4,819	1,288
Total fair value adjustments		(4,206)	(693)	(4,756)	(1,413)
Gross profit		6,346	1,121	8,274	2,157
Operating expenses					
Sales and marketing		364	87	950	131
General and administrative		4,219	1,872	6,680	3,208
Share-based payments	16(b),19	950	439	1,724	631
Depreciation and amortization	11,12	323	228	608	429
Total operating expenses		5,856	2,626	9,962	4,399
Operating income (loss)		490	(1,505)	(1,688)	(2,242)
Other income (expense)					
Interest income (expense)		(37)	13	(59)	(137)
Share of income from Whistler investment	9	3	313	44	416
Gain on other investments	10	-	1,330	221	1,271
Total other income (expense)		(34)	1,656	206	1,550
Income (loss) before income taxes		456	151	(1,482)	(692)
Income tax recovery	21	(267)	(23)	(1,155)	(22)
Net income (loss)		\$ 723	\$ 174	\$ (327)	\$ (670)
Other comprehensive income					
Gain on revaluation and disposal of other investments, net of tax	10,21	39	11	4	694
Comprehensive income (loss)		\$ 762	\$ 185	\$ (323)	\$ 24
Net income (loss) per share					
Basic and diluted	18	\$ 0.00	\$ 0.00	\$ (0.00)	\$ (0.01)
Weighted average number of outstanding shares					
Basic	18	175,529,196	132,647,546	166,343,078	128,824,503
Diluted	18	211,524,230	167,787,028	166,343,078	128,824,503

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

Cronos Group Inc.

Unaudited Condensed Interim Consolidated Statements of Changes in Equity

For the three and six months ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except number of share amounts)

	Notes	Number of shares	Share capital	Shares to be issued	Share-based reserve		Accumulated deficit	Accumulated other comprehensive income	Total
					Warrants	Stock options			
Balance at January 1, 2017		121,725,748	\$ 33,590	\$ -	\$ 3,983	\$ 735	\$ (6,215)	\$ 1,584	\$ 33,677
Shares issued	15(a)	7,705,000	17,336	-	-	-	-	-	17,336
Share issuance costs		-	(1,322)	-	-	-	-	-	(1,322)
Vesting of options	16(b)	-	-	-	-	631	-	-	631
Options exercised	16(b)	394,163	689	-	-	(247)	-	-	442
Warrants exercised	16(a)	3,317,416	1,272	-	(383)	-	-	-	889
Unrealized gains reclassified to net income	10	-	-	-	-	-	-	(691)	(691)
Net loss		-	-	-	-	-	(670)	-	(670)
Other comprehensive income	10	-	-	-	-	-	-	694	694
Balance at June 30, 2017		<u>133,142,327</u>	<u>\$ 51,565</u>	<u>\$ -</u>	<u>\$ 3,600</u>	<u>\$ 1,119</u>	<u>\$ (6,885)</u>	<u>\$ 1,587</u>	<u>\$ 50,986</u>
Balance at January 1, 2018		149,360,603	\$ 83,559	\$ -	\$ 3,364	\$ 2,289	\$ (3,724)	\$ 880	\$ 86,368
Shares issued	15(a)	15,677,143	146,032	-	-	-	-	-	146,032
Share issuance costs		-	(9,444)	-	-	-	-	-	(9,444)
Vesting of options	16(b)	-	-	-	-	1,724	-	-	1,724
Options exercised	16(b)	353,339	682	-	-	(142)	-	-	540
Warrants exercised	16(a)	11,364,335	3,852	-	(1,496)	-	-	-	2,356
Shares to be issued	15(c)	-	-	17	-	-	-	-	17
Share appreciation rights	16(b)	150,215	61	-	-	(61)	-	-	-
Net loss		-	-	-	-	-	(327)	-	(327)
Other comprehensive loss	10,21	-	-	-	-	-	-	4	4
Balance at June 30, 2018		<u>176,905,635</u>	<u>\$ 224,742</u>	<u>\$ 17</u>	<u>\$ 1,868</u>	<u>\$ 3,810</u>	<u>\$ (4,051)</u>	<u>\$ 884</u>	<u>\$ 227,270</u>

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

Cronos Group Inc.
Unaudited Condensed Interim Consolidated Statements of Cash Flows
For the three and six months ended June 30, 2018 and June 30, 2017
(in thousands of CDN \$)

	Notes	Three Months Ended June 30,		Six Months Ended June 30,	
		2018	2017	2018	2017
Operating activities					
Net income (loss)		\$ 723	\$ 174	\$ (327)	\$ (670)
Items not affecting cash:					
Unrealized change in fair value of biological assets	5,6	(6,831)	(1,122)	(9,575)	(2,701)
Realized fair value adjustments on inventory sold in the period	5,6	2,625	429	4,819	1,288
Share-based payments	16(b),19	950	439	1,724	631
Depreciation and amortization	11,12	575	228	1,115	429
Share of income from Whistler investment	9	(3)	(313)	(44)	(416)
Gain on other investments	10	-	(1,330)	(221)	(1,271)
Deferred income tax recovery	21	(267)	(23)	(1,155)	(22)
Foreign exchange loss (gain)		4	-	(12)	-
		(2,224)	(1,518)	(3,676)	(2,732)
Net changes in non-cash working capital:					
Accounts receivable		(318)	(55)	(1,704)	(191)
Sales taxes receivable		(2,686)	-	(3,838)	-
Prepays and other receivables		544	(2,087)	(3,322)	(2,152)
Biological assets		4,422	1,079	6,398	1,711
Inventory		(5,945)	(883)	(8,737)	(2,093)
Accrued interest on loan receivable		-	-	-	(5)
Accounts payable and other liabilities		(659)	136	(5,750)	208
Cash flows used in operating activities		(6,866)	(3,328)	(20,629)	(5,254)
Investing activities					
Repayment of purchase price liability		-	-	-	(1,299)
Investment in Whistler	9	-	(1,076)	-	(1,076)
Investment in ABcann Global Corporation	10	-	(1,016)	-	(1,016)
Proceeds from sale of other investments	10	280	1,683	967	1,771
Payment to exercise ABcann Global Corporation warrants	10	-	-	(113)	-
Advances of promissory note receivable	8	(378)	-	(1,304)	-
Purchase of property, plant and equipment	11	(30,025)	(3,494)	(37,667)	(5,529)
Purchase of intangible assets	12	(38)	-	(169)	-
Cash flows used in investing activities		(30,161)	(3,903)	(38,286)	(7,149)
Financing activities					
Proceeds from exercise of warrants	15(b)	132	245	1,412	889
Proceeds received for shares to be issued	15(c)	-	-	961	-
Proceeds from exercise of options	16(b)	467	185	540	442
Proceeds from share issuance	15(a)	100,032	-	146,032	17,336
Share issuance costs		(6,363)	-	(9,444)	(1,322)
Payment of accrued interest on construction loan	14	-	-	(185)	-
Repayment of mortgage payable		-	(4,000)	-	(4,000)
Cash flows provided by (used in) financing activities		94,268	(3,570)	139,316	13,345
Net change in cash		57,241	(10,801)	80,401	942
Cash - beginning of period		32,368	15,207	9,208	3,464
Cash - end of period		<u>\$ 89,609</u>	<u>\$ 4,406</u>	<u>\$ 89,609</u>	<u>\$ 4,406</u>
Supplemental cash flow information					
Interest paid		\$ 189	\$ 80	\$ 496	\$ 200

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

1. Nature of business

Cronos Group Inc. ("**Cronos Group**" or the "**Company**"), was incorporated under the *Business Corporations Act* (Ontario). Cronos Group is a publicly traded corporation, with its head office located at 720 King Street West, Suite 320, Toronto, Ontario, M5V 2T3. The Company's common shares are currently listed on the Toronto Stock Exchange ("**TSX**") and Nasdaq Global Market under the trading symbol "CRON".

Hortican Inc. ("**Hortican**"), is a wholly owned subsidiary of Cronos Group, incorporated under the *Canada Business Corporations Act* ("**CBCA**").

Cronos Group operates two wholly owned licensed producers and sellers ("**Licensed Producers**") of medical cannabis pursuant to the provisions of the *Controlled Drugs and Substances Act* ("**CDSA**") and its relevant regulation, the *Access to Cannabis for Medical Purposes Regulations* ("**ACMPR**"), namely Peace Naturals Project Inc. ("**Peace Naturals**"), which has production facilities near Stayner, Ontario, and Original BC Ltd. ("**OGBC**"), which has a production facility in Armstrong, British Columbia. Currently, Cronos Group sells dried cannabis flower and cannabis oils under its medical cannabis brand, Peace Naturals.

OGBC was incorporated as In the Zone Produce Ltd. ("**In the Zone**") under the *Business Corporations Act* (British Columbia) and was acquired by Hortican on November 5, 2014. In the Zone changed its name to OGBC on October 16, 2017, and was continued under the CBCA on the same day. OGBC is a Licensed Producer pursuant to the provisions of the ACMPR and the CDSA. On February 26, 2014, Health Canada issued an initial cultivation license to OGBC under the ACMPR which has since been amended and supplemented. OGBC's current license has an effective term from February 28, 2017 to February 28, 2020 and grants OGBC the right to engage in the production and sale of dried cannabis flower. The license was amended to reflect its name change on October 20, 2017.

Peace Naturals was incorporated under the CBCA, and was acquired by Hortican on September 6, 2016. Peace Naturals is a Licensed Producer pursuant to the provisions of the ACMPR and the CDSA. On October 31, 2013, Health Canada issued an initial license to Peace Naturals for activities related to the production and sale of dried cannabis flower under the ACMPR, which has since been amended and supplemented. Peace Naturals' current license has an effective term from November 1, 2016 to November 1, 2019 and grants Peace Naturals the right to engage in, among other things, the production and sale of dried cannabis flower, cannabis resin, cannabis seeds, cannabis plants, and cannabis oils. On January 22, 2018, the Company announced that Peace Naturals received a dealer's license pursuant to the *Narcotic Control Regulations* and CDSA from Health Canada, which allows Peace Naturals to export medical cannabis extracts, including concentrated oil and resin products, internationally.

Cronos Australia PTY Ltd. ("**Cronos Australia**") was incorporated under the *Corporations Act 2001* (Australia) on December 6, 2016 by Cronos Group. Cronos Group holds 50% of the outstanding shares of Cronos Australia.

Indigenous Roots Inc. and Cronos Indigenous Holdings Inc. were incorporated under the CBCA on December 14, 2016 and March 16, 2017, respectively. Both corporations are wholly owned by Hortican. These two corporations, along with a third party limited partnership, formed Indigenous Roots LP on April 18, 2017.

Cronos Global Holdings Inc. ("**Cronos Global**") was incorporated under the CBCA on April 25, 2017 by Hortican. Cronos Global will be the holding company for the Company's future global operations.

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

2. Basis of presentation

The unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2018 and June 30, 2017, have been prepared in accordance with International Accounting Standard ("IAS") 34, Interim Financial Reporting. The accounting policies adopted in the preparation of the unaudited condensed interim consolidated financial statements are consistent with those followed in the preparation of the Company's audited annual consolidated financial statements for the year ended December 31, 2017, except for the adoption of new standards effective as of January 1, 2018. The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. The Company applies, for the first time, International Financial Reporting Standard ("IFRS") 15 Revenue from Contracts with Customers and IFRS 9 Financial Instruments. As required by IAS 34, the nature and effect of these changes are disclosed in Note 3.

The unaudited condensed interim consolidated financial statements do not conform in all respects to the requirements of IFRS as issued by the International Accounting Standards Board ("IASB") for annual financial statements. Accordingly, these unaudited condensed interim consolidated financial statements should be read in conjunction with the December 31, 2017 audited consolidated financial statements and notes.

These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the "**Board**") on August 13, 2018.

(a) Basis of consolidation

These unaudited condensed interim consolidated financial statements include the accounts of Cronos Group Inc., and its wholly owned subsidiaries, Hortican Inc., OGBC, Peace Naturals, Indigenous Roots Inc., Cronos Indigenous Holdings Inc., and Cronos Global. All intercompany transactions, balances, revenues and expenses have been eliminated upon consolidation. The Company applies the acquisition method to account for business combinations. Acquisition related costs are expensed as incurred.

(b) Basis of measurement

Apart from certain assets and liabilities measured at fair value as required under certain IFRSs, the unaudited condensed interim consolidated financial statements have been presented and prepared on the basis of historical cost.

(c) Functional and presentation currency

These unaudited condensed interim consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and all of its subsidiaries.

(d) Estimates and critical judgments by management

The preparation of these unaudited condensed interim consolidated financial statements in conformity with IAS 34 requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are reviewed periodically and adjustments are made as appropriate in the year they become known. Items for which actual results may differ materially from these estimates are described in the following section.

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

(i) Warrants and options

Warrants and options are initially valued at fair value, based on the application of the Black-Scholes option pricing model. This pricing model requires management to make various assumptions and estimates which are susceptible to uncertainty, including the volatility of the share price, expected dividend yield, expected term of the warrant or option and expected risk-free interest rate.

(ii) Useful lives and impairment of long-lived assets

Long-lived assets are defined as property, plant and equipment and intangible assets with finite lives. Depreciation and amortization are dependent upon estimates of useful lives and impairment is dependent upon estimates of recoverable amounts. These are determined through the exercise of judgment, and are dependent upon estimates that take into account factors such as economic and market conditions, frequency of use, anticipated changes in laws, and technological improvements.

(iii) Impairment of cash-generating units and goodwill

The impairment test for cash generating units ("CGUs") to which goodwill is allocated is based on the value in use of the CGU, determined in accordance with the expected cash flow approach. The calculation is based on assumptions used to estimate future cash flows, the cash flow growth rate and the discount rate.

(iv) Fair value of privately held financial assets classified as fair value through other comprehensive income

The Company's management considers specific information about the investee companies, trends in general market conditions, and the share performance of similar publicly traded companies when valuing the Company's privately held investments.

Management considers the following factors to indicate a change in the fair value, or impairment of, a privately held investment, and may adjust the value if:

- a. there has been significant subsequent equity financing provided by outside investors at a value which differs from the current recorded value of the investee company, in which case the fair value of the investment is adjusted to equal the value at which that financing took place;
- b. there have been significant corporate, political, legal, or operating events affecting the investee company such that management believes they will materially impact the investee company's prospects and therefore its fair value. In these circumstances, the adjustment to fair value of the investment will be based on management's judgment;
- c. the investee company is placed into receivership or bankruptcy;
- d. based on financial information received from the investee company, it is evident that the investee company is unlikely to be able to continue as a going concern;
- e. receipt or denial by the investee company of medical marijuana licenses from Health Canada, which allow the investee company to initiate or continue operations; and
- f. management changes by the investee company that the Company's management believes will have an impact on the investee company's ability to achieve its objectives and build value for shareholders.

(v) Income taxes

Income taxes and tax exposures recognized in the unaudited condensed interim consolidated financial statements reflect management's best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

(vi) Biological assets and inventory

Biological assets, consisting of cannabis plants, are measured at fair value less costs to sell. At the point of harvest, the biological assets are transferred to inventory at fair value less costs to sell. As a result, critical estimates related to the valuation of biological assets are also applicable to inventory.

Determining the fair value less costs to sell requires the Company to make assumptions about the expected future yield from the cannabis plants, the value associated with each stage of the plants' growth cycle, estimated selling price, costs to convert harvested cannabis into finished goods, and costs to sell. The Company's estimates are, by their nature, subject to change.

3. Adoption of new accounting pronouncements

(a) Amendments to IFRS 2 Share-based payments

The amendments to IFRS 2 clarify how to account for certain types of share-based payment transactions. The amendments provide requirements on the accounting for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments, share-based payment transactions with a net settlement feature for withholding tax obligations, and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The effective date of these amendments was January 1, 2018. The Company has adopted these amendments as of the effective date and has assessed no significant changes as a result of the adoption of these amendments on the current period.

(b) IFRS 15 Revenue from contracts with customers

IFRS 15 was issued by the IASB in May 2014 and specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. IFRS 15 became effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. The Company has adopted this new standard as of its effective date using the full retrospective method of adoption, and have assessed no significant changes as a result of the adoption of this new standard on the current period.

Under IFRS 15, the revenue recognition model has changed from one based on the transfer of risks and rewards of ownership to the transfer of control. The Company's contracts with customers for the sales of dried cannabis and cannabis oil include one performance obligation, a promise in a contract with a customer to transfer a good or service. As the transfer of risks and rewards generally coincides with the transfer of control at a point in time, upon shipment or delivery, depending on the contract, the timing and amount of revenue considering discounts, rebates, and variable consideration, recognized from this principal revenue stream has not changed as a result of the adoption of this new standard.

The following is the Company's revenue recognition policy in accordance with IFRS 15:

(i) Revenue recognition

Revenue is recognized at the transaction price, which is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties. The Company's contracts with customers for the sales of dried cannabis and cannabis oil include one performance obligation. The Company has concluded that revenue from the sale of these products should be recognized at the point in time when control of the assets is transferred to the customer, which is on shipment or delivery, depending on the contract.

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)***(c) IFRS 9 Financial instruments**

IFRS 9 addresses classification and measurement of financial assets and replaces the multiple category and measurement models in IAS 39 for debt instruments with a new mixed measurement model having only three categories: amortized cost, fair value through other comprehensive income, and fair value through profit or loss. IFRS 9 also replaces the models for measuring equity instruments and such instruments are either recognized at fair value through profit or loss or at fair value through other comprehensive income. The effective date of this standard was January 1, 2018. The Company has adopted this new standard as of its effective date on a retrospective basis with the exception of financial assets that were derecognized at the date of initial application, January 1, 2018. The 2017 comparatives were not restated. As a result of the new classification model and measurement requirements under IFRS 9, the Company has elected to classify the available-for-sale investments as fair value through other comprehensive income investments. Under this classification, there is no recycling of gains or losses from accumulated other comprehensive income to profit or loss. Due to the adoption of IFRS 9, during the three and six months ended June 30, 2018, a net gain (loss) of approximately \$(224) and \$294 respectively on the disposal of investments classified as fair value through other comprehensive income was recorded in other comprehensive income rather than profit or loss during the period. The new classification and measurement of the Company's financial assets are as follows:

(i) Equity instruments at fair value through other comprehensive income ("FVOCI")

This category only includes equity instruments, which the Company intends to hold for the foreseeable future and which the Company has irrevocably elected to so classify upon initial recognition or transition. The Company classified its quoted and unquoted equity instruments as equity instruments at FVOCI. Equity instruments in this category are subsequently measured at fair value with changes recognized in other comprehensive income, with no recycling of gains or losses to profit or loss upon derecognition. Dividend income is recognized in earnings. Equity instruments at FVOCI are not subject to an impairment assessment under IFRS 9.

(ii) Amortized cost

This category includes financial assets that are held within a business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the solely principal and interest ("SPPI") criterion. Financial assets classified in this category are carried at amortized cost using the effective interest method.

(iii) Fair value through profit or loss

This category includes derivative instruments as well as quoted equity instruments which the Company has not irrevocably elected, at initial recognition or transition, to classify at FVOCI. This category would also include debt instruments whose cash flow characteristics fail the SPPI criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in profit or loss.

The assessment of the Company's business models was made as of the date of initial application, January 1, 2018, and then applied retrospectively to those financial assets that were not derecognized before January 1, 2018.

	IAS 39	IFRS 9
Financial assets		
Cash	Fair value through profit or loss	Fair value through profit or loss
Accounts receivable	Amortized cost	Amortized cost
Promissory note receivable	Amortized cost	Amortized cost
Loan receivable	Amortized cost	Amortized cost
Other investments	Available-for-sale	FVOCI
Financial liabilities		
Accounts payable and other liabilities	Amortized cost	Amortized cost
Construction loan payable	Amortized cost	Amortized cost

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

(iv) Impairment of financial assets

The adoption of IFRS 9 has fundamentally changed the Company's accounting of impairment losses for financial assets by replacing IAS 39's incurred loss approach with a forward-looking expected credit loss ("ECL") approach. IFRS 9 requires the Company to record an allowance for ECLs for all debt financial assets not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at a rate approximating the asset's original effective interest rate.

4. New and revised standards and interpretations issued but not yet effective

(a) IFRS 16 Leases

IFRS 16 was issued in January 2016 and replaces the previous guidance on leases. This standard provides a single recognition and measurement model to be applied by lessees to leases, with required recognition of assets and liabilities for most leases. This standard is effective for annual periods beginning on or after January 1, 2019, with early adoption permitted if the Company is also applying IFRS 15, Revenue from Contracts with Customers. The Company will adopt this new standard as of its effective date. The Company is currently evaluating the impact of the adoption of this new standard on its condensed interim consolidated financial statements.

(b) IFRIC 23 Uncertainty over income tax treatments

IFRIC 23 clarifies the application of recognition and measurement requirements in IAS 12, Income Taxes, when there is uncertainty over income tax treatments. It specifically addresses whether an entity considers each tax treatment independently or collectively, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates, and how an entity considers changes in facts and circumstances. IFRIC 23 will be effective for the Company's fiscal year beginning on January 1, 2019, with earlier application permitted. The Company is currently assessing the impact of the adoption of this standard on its condensed interim consolidated financial statements.

5. Accounting Changes

(a) Change in estimate

The Company has revised its estimate of the useful life of the Health Canada Licenses, described in Note 12. Previously, the Company estimated that the licenses had an indefinite life. During the three months ended, March 31, 2018, the Company has revised its estimate, and assessed that the licenses have an estimated useful life equal to the remaining useful life of the corresponding facilities.

(b) Change in accounting policy

During the three months ended June 30, 2018, the Company made a voluntary change in accounting policy to capitalize the direct and indirect costs attributable to the biological asset transformation. The previous accounting policy was to expense these costs as period costs. The new accounting policy is as follows:

(i) Biological assets

The Company measures biological assets consisting of cannabis plants at fair value less costs to sell up to the point of harvest. Production costs related to the transformation of biological assets to the point of harvest are capitalized, which become the cost basis of the biological assets, and are then revalued to fair value less costs to sell at the end of the period. Agricultural produce consisting of cannabis is measured at fair value less costs to sell at the point of harvest, which becomes the basis for the cost of inventory after harvest. Gains or losses arising from changes in fair value less costs to sell, excluding capitalized production costs, are included under fair value adjustments within the statement of operations. Upon harvest, capitalized production costs are transferred to inventory and are included in inventory expensed to cost of sales when the inventory is sold.

The new accounting policy provides more reliable and relevant information to users as the gross profit before fair value adjustments only considers the costs incurred on inventory sold during the year, and excludes costs incurred on the biological transformation until the related harvest is sold. The following demonstrates the change for each prior period presented. There is no impact of this policy change on gross profit, net income (loss), basic and diluted earnings per share, the statement of financial position, or the statement of changes in equity on the current or any prior period.

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

	Three Months Ended June 30, 2018		Three Months Ended June 30, 2017	
	Original accounting policy	New accounting policy	Original accounting policy	New accounting policy
Statement of Operations and Comprehensive Income (Loss)				
Cost of sales				
Inventory expensed to cost of sales, before fair value adjustments	\$ 259	\$ 1,254	\$ 55	\$ 215
Production costs	1,996	-	174	-
Total cost of sales (recovery)	2,255	1,254	229	215
Gross profit before fair value adjustments	1,139	2,140	414	428
Fair value adjustments:				
Unrealized change in fair value of biological assets	(8,827)	(6,831)	(1,296)	(1,122)
Realized fair value adjustments on inventory sold in the period	3,620	2,625	589	429
Total fair value adjustments	(5,207)	(4,206)	(707)	(693)
Gross profit	<u>\$ 6,346</u>	<u>\$ 6,346</u>	<u>\$ 1,121</u>	<u>\$ 1,121</u>

	Six Months Ended June 30, 2018		Six Months Ended June 30, 2017	
	Original accounting policy	New accounting policy	Original accounting policy	New accounting policy
Statement of Operations and Comprehensive Income (Loss)				
Cost of sales				
Inventory expensed to cost of sales, before fair value adjustments	\$ 780	\$ 2,821	\$ 125	\$ 413
Production costs	3,710	-	409	-
Total cost of sales (recovery)	4,490	2,821	534	413
Gross profit before fair value adjustments	1,849	3,518	623	744
Fair value adjustments:				
Unrealized change in fair value of biological assets	(13,285)	(9,575)	(3,110)	(2,701)
Realized fair value adjustments on inventory sold in the period	6,860	4,819	1,576	1,288
Total fair value adjustments	(6,425)	(4,756)	(1,534)	(1,413)
Gross profit	<u>\$ 8,274</u>	<u>\$ 8,274</u>	<u>\$ 2,157</u>	<u>\$ 2,157</u>

	Three Months Ended June 30, 2018		Three Months Ended June 30, 2017	
	Original accounting policy	New accounting policy	Original accounting policy	New accounting policy
Statement of Cash Flows				
Operating activities				
Items not affecting cash:				
Unrealized change in fair value of biological assets	\$ (8,827)	\$ (6,831)	\$ (1,296)	\$ (1,122)
Realized fair value adjustments on inventory sold in the period	3,620	2,625	589	429
Net changes in non-cash working capital:				
Increase in biological assets	6,418	4,422	1,253	1,079
Increase in inventory	(6,940)	(5,945)	(1,043)	(883)
Net effect on cash flows used in operating activities	<u>\$ (5,729)</u>	<u>\$ (5,729)</u>	<u>\$ (497)</u>	<u>\$ (497)</u>

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

	Six Months Ended June 30, 2018		Six Months Ended June 30, 2017	
	Original accounting policy	New accounting policy	Original accounting policy	New accounting policy
Statement of Cash Flows				
Operating activities				
Items not affecting cash:				
Unrealized change in fair value of biological assets	\$ (13,285)	\$ (9,575)	\$ (3,110)	\$ (2,701)
Realized fair value adjustments on inventory sold in the period	6,860	4,819	1,576	1,288
Net changes in non-cash working capital:				
Increase in biological assets	10,108	6,398	2,120	1,711
Increase in inventory	(10,778)	(8,737)	(2,381)	(2,093)
Net effect on cash flows used in operating activities	\$ (7,095)	\$ (7,095)	\$ (1,795)	\$ (1,795)

6. Biological assets and inventory

The Company's biological assets consist of cannabis plants. The changes in the carrying amount of the biological assets are as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018 (Note 5)	2017 (Note 5)	2018 (Note 5)	2017 (Note 5)
Biological assets - beginning of period	\$ 4,490	\$ 2,742	\$ 3,722	\$ 1,795
Unrealized change in fair value of biological assets	6,831	1,122	9,575	2,701
Transferred to inventory upon harvest	(4,422)	(1,079)	(6,398)	(1,711)
Biological assets - end of period	<u>\$ 6,899</u>	<u>\$ 2,785</u>	<u>\$ 6,899</u>	<u>\$ 2,785</u>

As of June 30, 2018, it is expected that the Company's biological assets will ultimately yield approximately 2,426 kg of medical cannabis (December 31, 2017 - 1,695 kg). As at June 30, 2018, the Company has 14,440 plants that are biological assets (December 31, 2017 - 7,353 plants).

The direct and indirect costs related to biological assets and inventory are allocated as follows:

Nature of cost	Allocation basis (i)
Consumables (insect control, fertilizers, soil)	100% allocated to production costs as these costs are incurred to support plant growth
Facilities labour (including salaries and benefits)	Allocated based on job descriptions of various personnel of which 25% allocated to processing costs and 75% allocated to production costs
Quality control labour (including salaries and benefits)	Allocated based on time spent on quality control of plants versus harvested product of which 50% allocated to production costs to ensure plant health and 50% allocated to processing costs, to test quality of harvested product
Production labour (including salaries and benefits)	Allocated based on job descriptions of various personnel of which 20% allocated to processing costs and 80% allocated to production costs
Utilities	Allocated based on estimates of usage of which 10% allocated to processing costs and 90% allocated to production costs
Property taxes, amortization, security	Allocated based on estimates of square footage of which 20% allocated to processing costs, 50% allocated to production costs, and 30% allocated to operating expenses
Packaging costs	100% allocated to processing costs

- (i) Processing costs are capitalized to inventory and then recognized in inventory expensed to cost of sales when the inventory is sold. Production costs are capitalized to biological assets as a cost directly attributable to growing the plants. Refer to Note 5(b)(i).

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

The fair value of the biological assets at the point of harvest becomes the initial deemed cost for the inventory. Subsequent to harvest, all direct and indirect costs related to inventory are capitalized to inventory to the extent that cost is less than net realizable value. Upon sale of the inventory, these costs are recorded in cost of sales as inventory expensed to cost of sales in the statement of operations and comprehensive income (loss), which includes the realized fair value increments on inventory sold during the period.

All of the plants are to be harvested into medical cannabis and as at June 30, 2018, on average, the plants were 42% complete (December 31, 2017 - 46%). This is a time measure of the plants' age relative to the estimated growth cycle of 16 weeks.

The Company's valuation model for determining the fair value of biological assets is based on the stage of plant growth relative to the number of weeks in the growth cycle, multiplied by the estimated harvest yield, multiplied by the estimated selling price less costs to sell per gram. Management has assessed that there is a linear relationship between plant growth and fair value, as there is no significant initial cost associated with the plant, no observable market for a partially grown plant, and costs are incurred consistently over the term of the plant's growth cycle. The estimates of growing cycle, harvest yield, and costs per gram are based on the Company's historical results. The estimate of the selling price per gram is based on the Company's historical sales in addition to the Company's expected sales price going forward.

The Company has made the following significant estimates in this valuation model:

- Average number of weeks in the growing cycle is sixteen weeks from propagation to harvest
- Average harvest yield of whole flower and trim is 168 grams per plant
- Average selling price of whole flower is \$8.50 per gram
- Processing costs include drying and curing, testing and packaging, and post-harvest overhead allocation, and oil extraction costs estimated to be \$0.87 per gram
- Selling costs include shipping, order fulfillment, and labelling, estimated to be \$0.47 per gram

The Company has performed the following sensitivity analysis on the significant unobservable inputs as at June 30, 2018:

Input	Impact of 5% decrease in input
Selling price per gram	Decrease in biological assets by \$397 and decrease in inventory by \$583
Harvest yield per gram	Decrease in biological assets by \$336
Average number of weeks in growing cycle	Increase in biological assets by \$353
Processing costs per gram	Increase in biological assets by \$39 and increase in inventory by \$7
Selling costs per gram	Increase in biological assets by \$22 and increase in inventory by \$32

These inputs are level 3 on the fair value hierarchy, and are subject to volatility and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods.

Inventory as at June 30, 2018 consisted of the following:

	As at June 30, 2018	As at December 31, 2017
Dry cannabis		
Finished goods	\$ 9,264	\$ 6,145
Work-in-process	1,566	1,630
	<u>10,830</u>	<u>7,775</u>
Cannabis oils		
Finished goods	695	332
Work-in-process	353	-
	<u>1,048</u>	<u>332</u>
Raw materials	171	183
Supplies and consumables	285	126
	<u>\$ 12,334</u>	<u>\$ 8,416</u>

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

As at June 30, 2018, the Company held 1,166 kg of dry cannabis and 350 L of cannabis oil as finished goods (December 31, 2017 - 815 kg and 137 L, respectively). In addition, the Company held 218 kg (December 31, 2017 - 243 kg) of harvested cannabis in the processing stage, and 187 L (December 31, 2017 - nil) of harvested cannabis in the oil extraction processing stage, classified as work-in-process as at June 30, 2018. Finally, 0.267 kg of seeds were held by the Company as raw materials (December 31, 2017 - 0.288 kg).

The amount of inventory expensed to cost of sales, before fair value adjustments, during the period is as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018 (Note 5)	2017 (Note 5)	2018 (Note 5)	2017 (Note 5)
Inventory expensed to cost of sales	\$ 3,879	\$ 644	\$ 7,640	\$ 1,701
Realized fair value adjustments on inventory sold in the period (i)	(2,625)	(429)	(4,819)	(1,288)
Inventory expensed to cost of sales, before fair value adjustments (ii)	<u>\$ 1,254</u>	<u>\$ 215</u>	<u>\$ 2,821</u>	<u>\$ 413</u>

(i) This figure is included in the statement of operations as a fair value adjustment.

(ii) This figure is recorded in the statement of operations as cost of sales.

7. Loan receivable

	As at June 30, 2018	As at December 31, 2017
Loan receivable from Evergreen Medicinal Supply Inc. ("Evergreen") (i)	\$ 265	\$ 265
Add: Accrued interest	49	49
Loan receivable	<u>\$ 314</u>	<u>\$ 314</u>

(i) The loan is due on demand. The loan accrued interest at 8% per year, up to March 31, 2017, calculated and payable annually in arrears.

8. Promissory note receivable

The Company announced a strategic joint venture in Israel ("**Cronos Israel**") with the Israeli agricultural collective settlement Kibbutz Gan Shmuel ("**Gan Shmuel**") for the production, manufacture and distribution of medical cannabis. Following the receipt of approval from the Israeli Ministry of Health to issue equity interests, the Company will hold a 70% interest in each of the nursery and cultivation operations and a 90% interest in each of the manufacturing and distribution operations. Gan Shmuel has provided the Company a promissory note for monies advanced from the Company up to the sum of 2,700 Israeli Shekels ("**ILS**") (\$978). During the three months ended June 30, 2018, the Company advanced 900 ILS in excess of the 2,700 ILS promissory note receivable. As such, 900 ILS (\$326) receivable is unsecured. The promissory note shall be returned to Gan Shmuel on the date that is 12 months after the date of receipt of the final cannabis cultivation license.

9. Investment in Whistler

As at June 30, 2018, the investment represents an approximate 19.0% (December 31, 2017 - 20.3%) ownership in Whistler Medical Marijuana Corporation ("**Whistler**"), incorporated in British Columbia, Canada. Whistler is a licensed producer and seller of medical marijuana with operations in British Columbia, Canada.

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

A reconciliation of the carrying amount of the investment is as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Balance - beginning of period	\$ 3,848	\$ 2,669	\$ 3,807	\$ 2,566
Purchase of additional shares	-	1,076	-	1,076
Company's share of income	3	313	44	416
Balance - end of period	<u>\$ 3,851</u>	<u>\$ 4,058</u>	<u>\$ 3,851</u>	<u>\$ 4,058</u>

10. Other investments

Other investments consist of investments in common shares and warrants of several companies in the medical cannabis industry. These investments, with the exception of shares of Evergreen and warrants of ABCann Global Corporation (now known as "VIVO Cannabis Inc.") ("**ABCann**"), were traded in an active market as of the relevant period end date and, as a result, had a reliably measurable fair value as of such period end dates.

	As at June 30, 2018	As at December 31, 2017
Fair value through other comprehensive income investments		
Canopy Growth Corporation (" Canopy ") (i)	\$ 425	\$ 877
Evergreen (iii)	300	300
	<u>\$ 725</u>	<u>\$ 1,177</u>
Fair value through profit or loss investment		
ABCann - share warrants (ii and v)	-	170
	<u>\$ 725</u>	<u>\$ 1,347</u>

The gains (losses) recognized upon the increase (decrease) in the fair value of other investments was as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Gain recognized in net income (loss)				
Canopy (i)	\$ -	\$ -	\$ -	\$ 36
ABCann - shares (ii)	-	1,038	-	1,038
ABCann - share warrants (ii and v)	-	292	221	197
	<u>\$ -</u>	<u>\$ 1,330</u>	<u>\$ 221</u>	<u>\$ 1,271</u>
	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Gain (loss) recognized through other comprehensive income before taxes				
The Hydrothecary Corporation (iv)	\$ -	\$ (324)	\$ -	\$ 314
Canopy (i)	53	(80)	235	(35)
ABCann - shares (ii)	(34)	415	(224)	415
	<u>\$ 19</u>	<u>\$ 11</u>	<u>\$ 11</u>	<u>\$ 694</u>

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

- (i) During the six months ended June 30, 2018, the Company sold some of its shares of Canopy for proceeds of \$687 (June 30, 2017 - \$88).
- (ii) During the six months ended June 30, 2018, the Company exercised 182,927 share warrants for aggregate consideration of \$113, for additional shares of ABCann. Prior to the exercise, the share warrants were revalued to fair value using the Black-Scholes option pricing model. Subsequently, the Company sold all of its shares of ABCann for proceeds of \$280.

During the six months ended June 30, 2017, ABCann completed a reverse takeover with Panda Capital Inc. As a result of this transaction, ABCann began trading on the TSX. The Company subscribed for additional shares of ABCann of \$1,016 and sold certain shares of ABCann for proceeds of \$1,683 during the three months ended June 30, 2017.

- (iii) On March 16, 2017, Evergreen received a cultivation license under the ACMPR. As a result, the Company completed its subscription for a second tranche of shares of Evergreen for \$100 and exercised its option to acquire an additional 5% of the equity of Evergreen for \$500, for a total additional investment of \$600. However, Evergreen, through its counsel, has indicated that the Company is not entitled to any interest in Evergreen and has rejected the payment. The Company filed a statement of claim in the Supreme Court of British Columbia and Evergreen has filed a statement of defence. The Company intends to vigorously pursue the enforcement of its rights to acquire equity in Evergreen.
- (iv) During the six months ended June 30, 2017, BFK Capital Corp. acquired all of the outstanding shares of Hydrothecary Corporation, and began trading as Hydrothecary Corporation, (TSX: HEXO). As a result of this transaction, Hydrothecary Corporation executed a 6:1 stock split.
- (v) As at December 31, 2017, the fair value of the warrants was estimated using the Black-Scholes option pricing model with the following assumptions: risk free rate: 1.66%; volatility: 65%; share price: \$1.53 per share; expected life: 0.76 years; and dividend yield: Nil%.

11. Property, plant and equipment

Cost	As at		As at	
	January 1, 2018	Additions	June 30, 2018	
Land	\$ 1,558	\$ 19	\$ 1,577	
Building structures	11,518	1,780	13,298	
Furniture and equipment	134	293	427	
Computer equipment	148	87	235	
Security equipment	886	64	950	
Production equipment	2,481	246	2,727	
Road	137	-	137	
Leasehold improvements	1,497	87	1,584	
Equipment under finance lease	-	217	217	
Construction in progress	39,337	35,474	74,811	
	<u>\$ 57,696</u>	<u>\$ 38,267</u>	<u>\$ 95,963</u>	

During the six months ended June 30, 2018, there were non-cash additions from the capitalization of transaction costs and accrued interest on construction in progress amounting to \$383 (June 30, 2017 - \$Nil), refer to Note 14. As at June 30, 2018 the net carrying amount of property, plant, and equipment includes equipment held under finance lease with a net carrying amount of \$186 (December 31, 2017 - \$Nil), refer to Note 15.

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

	As at January 1, 2018	Additions	As at June 30, 2018
Accumulated depreciation			
Building structures	\$ 433	\$ 308	\$ 741
Furniture and equipment	43	28	71
Computer equipment	75	27	102
Security equipment	196	91	287
Production equipment	431	210	641
Road	10	3	13
Leasehold improvements	336	84	420
Equipment under finance lease	-	31	31
	<u>1,524</u>	<u>782</u>	<u>2,306</u>
Net book value	<u>\$ 56,172</u>		<u>\$ 93,657</u>

During the six months ended June 30, 2018, \$392 (June 30, 2017 - \$Nil) of depreciation expense was recorded as part of inventory expensed to cost of sales and production costs. An additional \$115 of depreciation expense remained capitalized in inventory as at June 30, 2018 (December 31, 2017 - \$Nil).

Cost	As at January 1, 2017	Additions	As at June 30, 2017
Land	\$ 1,558	\$ -	\$ 1,558
Building structures	2,761	1,296	4,057
Furniture and equipment	63	65	128
Computer equipment	88	14	102
Security equipment	474	189	663
Production equipment	2,106	813	2,919
Road	137	-	137
Leasehold improvements	1,429	-	1,429
Construction in progress	6,034	3,152	9,186
	<u>\$ 14,650</u>	<u>\$ 5,529</u>	<u>\$ 20,179</u>

Accumulated depreciation	As at January 1, 2017	Additions	As at June 30, 2017
Building structures	\$ 120	\$ 85	\$ 205
Furniture and equipment	18	12	30
Computer equipment	36	18	54
Security equipment	60	57	117
Production equipment	103	179	282
Road	5	3	8
Leasehold improvements	186	75	261
	<u>528</u>	<u>429</u>	<u>957</u>
Net book value	<u>\$ 14,122</u>		<u>\$ 19,222</u>

12. Intangible assets

Cost	As at January 1, 2018	Additions	As at June 30, 2018
Software	\$ -	\$ 169	\$ 169
Health Canada Licenses - OGBC	1,611	-	1,611
Health Canada Licenses - Peace Naturals	9,596	-	9,596
	<u>\$ 11,207</u>	<u>\$ 169</u>	<u>\$ 11,376</u>

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

	As at January 1, 2018	Additions	As at June 30, 2018
Accumulated amortization			
Software	\$ -	\$ 16	\$ 16
Health Canada Licenses - OGBC	-	50	50
Health Canada Licenses - Peace Naturals	-	267	267
	-	333	333
Net book value	<u>\$ 11,207</u>		<u>\$ 11,043</u>

	As at January 1, 2017	Additions	As at June 30, 2017
Cost			
Health Canada Licenses - OGBC	\$ 1,611	-	\$ 1,611
Health Canada Licenses - Peace Naturals	9,596	-	9,596
Net book value	<u>\$ 11,207</u>	<u>\$ -</u>	<u>\$ 11,207</u>

13. Goodwill

	As at January 1, 2018	Additions	As at June 30, 2018
OGBC	\$ 392	-	\$ 392
Peace Naturals	1,400	-	1,400
	<u>\$ 1,792</u>	<u>\$ -</u>	<u>\$ 1,792</u>

	As at January 1, 2017	Additions	As at June 30, 2017
OGBC	\$ 392	-	\$ 392
Peace Naturals	1,400	-	1,400
	<u>\$ 1,792</u>	<u>\$ -</u>	<u>\$ 1,792</u>

14. Construction loan payable

	As at June 30, 2018	As at December 31, 2017
First advance	\$ 6,304	\$ 6,304
Less: transaction costs (net of amortization)	(802)	(1,122)
Add: accrued interest	63	185
	<u>\$ 5,565</u>	<u>\$ 5,367</u>

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

On August 23, 2017, Peace Naturals, as borrower, signed a construction loan agreement with Romspen Investment Corporation as lender, to borrow \$40,000, to be funded by way of multiple advances. The aggregate advances are limited to \$35,000 until the lender receives an appraisal valuing the property in British Columbia at an amount of not less than \$8,000. The loan bears interest at a rate of 12% per annum, calculated and compounded monthly, in arrears, on the amounts advanced from the date of each advance. The term of the loan is two years, with the borrower's option to extend for another twelve months. The loan is guaranteed by Cronos Group, Hortican, OGBC, the responsible-person-in-charge and the senior-person-in-charge of OGBC and Peace Naturals. The loan is secured as follows:

- (a) first-ranking charge on the land owned by OGBC, Peace Naturals, and Hortican, (the "**Property**") with a net book value of approximately \$1,577 as at June 30, 2018 (December 31, 2017 - \$1,558);
- (b) first-ranking general assignment of all present and future leases of each Property;
- (c) general security agreements creating first-ranking security interests on all the personal property of Peace Naturals and the corporate guarantors including without limitation, goods, chattels, paper, documents, accounts, intangible assets, securities, monies, books and records;
- (d) specific assignment of each Property's right, title, and interest in the construction project for which the loan is being used to fund, including licenses, permits, plans and specifications, development approvals and agreements;
- (e) acknowledgement of the status and terms of any contracts affecting or with respect to each Property including without limitation, any pertaining to ownership, insurance, shared facilities, passageway agreements, or similar matters, confirming the good status of such contracts, and the rights of the lender under such contracts;
- (f) the subordination of all other indebtedness of Peace Naturals;
- (g) an unconditional, joint and several covenant by the guarantors as principal debtor for the performance of obligations by Peace Naturals, it being understood that the lender is not obliged to proceed against Peace Naturals or exhaust any security before proceeding against the guarantors;
- (h) assignment, postponement, and subordination by the corporate guarantors in favour of the lender;
- (i) assignment of all insurance policies with respect to each Property and the construction project;
- (j) pledge of the shares of Peace Naturals, OGBC, and Hortican;
- (k) an environmental indemnity from Peace Naturals and the corporate guarantors; and
- (l) deficiency and completion guarantee from Peace Naturals and the corporate guarantors.

15. Share capital

- (a) Common Shares

The Company is authorized to issue an unlimited number of no par value common shares.

The holders of the common shares are entitled to receive dividends which may be declared from time to time, and are entitled to one vote per share at shareholder meetings of the Company. All common shares are ranked equally with regards to the Company's residual assets.

During the six months ended June 30, 2018, the Company issued 15,677,143 (June 30, 2017 - 7,705,000) common shares for aggregate gross proceeds of \$146,032 (June 30, 2017 - \$17,336) through two bought deal offerings.

- (b) Special Shares

The Company is authorized to issue an unlimited number of special shares, issuable in series.

The special shares may be issued in one or more series and the Board is authorized to fix the number of shares in each series and to determine the designation, rights, privileges, restrictions and conditions attached to the shares in each series. No special shares have been issued since the Company's incorporation.

- (c) Shares to be issued

The Company received cash of \$17 for the exercise of options, for which common shares were not yet issued as of June 30, 2018. Refer to Note 16(b).

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)***16. Share-based payments****(a) Warrants**

The following is a summary of the changes in warrants for the period from January 1, 2017 to June 30, 2017:

	<u>Grant date</u>	<u>Exercise price</u>	<u>Number of warrants</u>	<u>Amount</u>
Balance at January 1, 2017			45,885,172	\$ 3,983
Exercise of warrants				-
January	January 30, 2014	\$ 0.71	(375,565)	(164)
January	January 18, 2013	0.08	(298,066)	-
March	October 8, 2015	0.31	(1,140,351)	(117)
April	October 28, 2015	0.31	(350,877)	(66)
April	January 18, 2013	0.08	(744,198)	-
May	January 18, 2013	0.08	(165,377)	-
May	October 28, 2015	0.31	(192,982)	(36)
June	January 18, 2013	0.08	(50,000)	-
Expiry of warrants			(19,210)	-
Balance at June 30, 2017			<u>42,548,546</u>	<u>\$ 3,600</u>

The following is a summary of the changes in warrants for the period from January 1, 2018 to June 30, 2018:

	<u>Grant date</u>	<u>Exercise price</u>	<u>Number of warrants</u>	<u>Amount</u>
Balance at January 1, 2018			38,654,654	\$ 3,364
Exercise of warrants				-
January	January 18, 2013	\$ 0.08	(2,898,784)	-
February	May 27, 2016	0.25	(2,128,112)	(391)
March	October 8, 2015	0.31	(766,086)	(78)
March	May 27, 2016	0.25	(1,179,497)	(217)
April	May 27, 2016	0.25	(3,851,316)	(710)
June	May 27, 2016	0.25	(540,540)	(100)
Expiry of warrants			(82,695)	-
Balance at June 30, 2018			<u>27,207,624</u>	<u>\$ 1,868</u>

As at June 30, 2018, the Company had outstanding warrants as follows:

<u>Grant date</u>	<u>Number of warrants</u>	<u>Exercise price</u>	<u>Expiry</u>
October 8, 2015	3,335,594	\$ 0.31	October 8, 2020
October 23, 2015	1,478,245	0.31	October 23, 2020
October 28, 2015	9,548	0.31	October 28, 2020
May 13, 2016	8,510,812	0.25	May 13, 2021
May 27, 2016	13,873,425	0.25	May 27, 2021
	<u>27,207,624</u>	<u>\$ 0.26</u>	

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

(b) Stock Options

(i) Stock Option Plans

The Company had adopted an amended and restated stock option plan dated May 26, 2015 (the “**2015 Stock Option Plan**”) which was approved by shareholders of the Company at the annual and general meeting of shareholders held on June 28, 2017. The 2015 Stock Option Plan allowed the Board to award options to purchase shares to certain directors, officers, key employees and service providers of the Company.

On June 28, 2018, the shareholders of the Company approved a new stock option plan (the “**2018 Stock Option Plan**”) which superseded the 2015 Stock Option Plan. No further awards will be granted under the 2015 Stock Option Plan; however shares may be purchased by the holders of any outstanding stock options previously issued under the 2015 Stock Option Plan.

Participants under the 2018 Option Plan are eligible to be granted options to purchase shares at an exercise price established upon approval of the grant by the Board. When options are granted, the exercise price is, with respect to a particular date, the closing price as reported by the TSX on the immediately preceding trading day (the “**Fair Market Value**”). The 2018 Option Plan does not authorize grants of options with an exercise price below the Fair Market Value.

Vesting conditions for grants of options are determined by the Board. The typical vesting for employee grants is quarterly vesting over five years, and the typical vesting for directors and executive officers is quarterly vesting over three to five years. The term of the options is established by the Board, provided that the term of an option may not exceed seven years from the date of the grant.

The 2018 Option Plan also provides for the issuance of share appreciation rights (“**SARs**”) in tandem with options. Each SAR entitles the holder to surrender to the Company, unexercised, the right to subscribe for shares pursuant to the related option and to receive from the Company a number of shares, rounded down to the next whole share, with a Fair Market Value on the date of exercise of each such SAR that is equal to the difference between such Fair Market Value and the exercise price under the related option, multiplied by the number of shares that cease to be available under the option as a result of the exercise of the SAR, subject to satisfaction of applicable withholding taxes and other source deductions. Each unexercised SAR terminates when the related option is exercised or the option terminates, including upon a change in control. Upon each exercise of a SAR in respect of a share covered by an option such option is cancelled and is of no further force or effect in respect of such share.

(ii) Summary of changes

The following is a summary of the changes in options for the period from January 1, 2017 to June 30, 2017:

	<u>Grant date</u>	<u>Exercise price</u>	<u>Number of options</u>	<u>Amount</u>
Balance at January 1, 2017			6,177,594	\$ 735
Exercise of options				
January	January 30, 2014	\$ 0.71	(32,009)	(14)
February	August 5, 2014	1.15	(32,000)	(23)
March	September 19, December 17, 2014	1.15	(171,695)	(104)
April	August 5, 2014	1.15	(93,000)	(66)
April	October 6, 2016	1.23	(30,416)	(15)
May	August 5, 2014	1.15	(35,043)	(25)
Issuance of options	April 12, 2017	3.14	3,299,000	
Vesting of issued options			-	631
Balance at June 30, 2017			<u>9,082,431</u>	<u>\$ 1,119</u>

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

The following is a summary of the changes in options for the period from January 1, 2018 to June 30, 2018:

	<u>Grant date</u>	<u>Exercise price</u>	<u>Number of options</u>	<u>Amount</u>
Balance at January 1, 2018			11,603,750	\$ 2,289
Issuance of options				
January	January 30, 2018	\$ 8.40	280,000	-
January	January 31, 2018	9.00	150,000	-
May	May 18, 2018	7.57	1,195,000	-
June	June 28, 2018	8.22	180,000	-
Exercise of options				
January	October 6, 2016	1.23	(8,333)	(4)
January	April 12, 2017	3.14	(2,291)	(4)
January	August 23, 2017	2.42	(1,041)	(1)
February	October 6, 2016	1.23	(20,800)	(10)
February	April 12, 2017	3.14	(2,500)	(4)
February	August 23, 2017	2.42	(2,291)	(3)
March	April 12, 2017	3.14	(2,000)	(3)
March	August 23, 2017	2.42	(3,000)	(4)
April	November 16, 2016	1.50	(300,000)	(101)
May	April 12, 2017	3.14	(125)	-
May	August 23, 2017	2.42	(125)	-
June	August 5, 2016	0.50	(83,333)	(20)
June	October 6, 2016	1.23	(91,333)	(46)
June	April 12, 2017	3.14	(833)	(1)
June	August 23, 2017	2.42	(1,667)	(2)
Expiry of options			(8,000)	-
Vesting of issued options			-	1,724
Balance at June 30, 2018			<u>12,881,078</u>	<u>\$ 3,810</u>

The weighted average share price at the dates the options were exercised during the six months ended June 30, 2018 was \$9.08 per share (June 2017 - \$2.61 per share).

As at June 30, 2018, the Company had outstanding and exercisable options as follows:

<u>Grant date</u>	<u>Vesting terms</u>	<u>Number of options</u>	<u>Weighted average</u>	
			<u>Exercise price</u>	<u>Remaining contractual life (years)</u>
August 5, 2016	Evenly over 48 months	1,058,333	\$ 0.50	3.10
October 6, 2016	Evenly over 48 months	3,457,618	1.23	3.27
November 21, 2016	Evenly over 48 months	182,000	1.84	3.40
April 12, 2017	Evenly over 48 months	3,288,251	3.14	3.79
August 23, 2017	Evenly over 48 months	2,889,876	2.42	4.15
November 9, 2017	Evenly over 48 months	200,000	3.32	4.36
January 30, 2018	Evenly over 48 months	280,000	8.40	4.59
January 31, 2018	Evenly over 48 months	150,000	9.00	4.59
May 18, 2018	Evenly over 48 months	1,195,000	7.57	4.88
June 28, 2018	Evenly over 60 months	180,000	8.22	5.00
Outstanding at June 30, 2018		<u>12,881,078</u>	<u>\$ 2.90</u>	<u>3.82</u>
Exercisable at June 30, 2018		<u>3,804,668</u>	<u>\$ 2.00</u>	<u>3.57</u>

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

These options shall expire at the earlier of 180 days of the death, disability or incapacity of the holder or five years after the date of issuance, and can only be settled in equity.

As at June 30, 2018, the weighted average exercise price of options outstanding was \$2.90 per option (December 31, 2017 - \$2.05 per option). The weighted average exercise price of options exercisable was \$2.00 per option (December 31, 2017 - \$1.71 per option).

(iii) Fair Value of Options Issued During the Period

The fair value of the options issued during the period was determined using the Black-Scholes option pricing model, using the following inputs:

	Six Months Ended June 30,	
	2018	2017
Share price at grant date (per share)	\$7.57 - \$9.00	\$ 3.27
Exercise price (per option)	\$7.57 - \$9.00	\$ 3.14
Risk free interest rate	2.01% - 2.23%	0.96%
Expected life of options (in years)	5	5
Expected annualized volatility	55%	55%
Expected dividend yield	0%	0%
Weighted average Black-Scholes value at grant date (per option)	\$3.72 - \$4.40	\$ 1.59

(iv) Expenses Arising from Share-based Payments

The total expenses arising from share-based payments recognized during the six months ended June 30, 2018 were \$1,724 (June 30, 2017 - \$631).

17. Revenue from contracts with customers

The following is the disaggregation of the Company's revenue from contracts with customers:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Dry cannabis	\$ 2,715	\$ 643	\$ 5,335	\$ 1,157
Cannabis oils	636	-	891	-
Other	43	-	113	-
Total revenue from contracts with customers	<u>\$ 3,394</u>	<u>\$ 643</u>	<u>\$ 6,339</u>	<u>\$ 1,157</u>

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)***18. Earnings (loss) per share**

Basic and diluted loss per share are calculated using the following numerators and denominators:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Numerator				
Net income (loss) attributable to common shareholders	\$ 723	\$ 174	\$ (327)	\$ (670)
Net income (loss) used in the computation of basic and diluted income (loss) per share	<u>\$ 723</u>	<u>\$ 174</u>	<u>\$ (327)</u>	<u>\$ (670)</u>
Denominator				
Weighted average number of common shares outstanding for computation of basic income (loss) per share	175,529,196	132,647,546	166,343,078	128,824,503
Dilutive effect of warrants	26,917,949	34,553,620	-	-
Dilutive effect of options	9,077,085	585,862	-	-
Weighted average number of common shares for computation of diluted loss per share	<u>211,524,230</u>	<u>167,787,028</u>	<u>166,343,078</u>	<u>128,824,503</u>

For the six months ended June 30, 2018 and 2017, all instruments were anti-dilutive.

19. Related party transactions and balances

The following is a summary of the Company's related party transactions during the period:

(a) Key management compensation

Key management personnel are persons responsible for planning, directing and controlling activities of an entity, and include executive and non-executive directors. Compensation provided to key management is as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Short-term employee benefits, including salaries and fees	\$ 110	\$ 106	\$ 219	\$ 212
Professional fees	58	-	116	71
Share-based payments	356	161	695	228
	<u>\$ 524</u>	<u>\$ 267</u>	<u>\$ 1,030</u>	<u>\$ 511</u>

As at June 30, 2018, there were no balances payable to members of key management (December 31, 2017 - \$Nil).

20. Commitments and contingencies

(a) The following is a summary of the Company's minimum operating lease obligations for its premises due in future fiscal years:

Remainder of 2018	\$ 44
2019	112
2020	96
2021	92
2022	95
2023	8
	<u>\$ 447</u>

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)*

In addition to the minimum lease payments, the Company is required to pay realty taxes and other occupancy costs.

(b) The following contingencies are related to Peace Naturals:

- (i) *MedCann Access Acquisition Claim.* 8437718 Canada Inc., 8437726 Canada Inc., Michael Blaine Dowdle, Rade Kovacevic, Kevin Furet and 9388036 Canada Inc. (collectively, the “**Plaintiffs**”) commenced a claim against Peace Naturals and a number of other parties, for \$15,000 in damages as a result of an alleged breach of obligations to them by terminating a share purchase transaction for the acquisition of the Plaintiffs’ company, MedCann Access. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend this claim; accordingly, no provision for loss has been recognized. On February 21, 2018, the parties began the discovery phase of the proceedings.
- (ii) *Warrants Claim.* Jeffrey Gobuty, brother to Mark Gobuty, former CEO of Peace Naturals, brought a claim against Peace Naturals for \$300 and for warrants valued at \$125 that were purportedly issued by Mark Gobuty, the former CEO of Peace Naturals. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend this claim. The plaintiff has not actively pursued this claim in over two years.
- (iii) *Former Employees' Unlawful Termination Claims.* Peace Naturals, Cronos Group and certain directors were served with claims by a former employee for damages of \$580 and 30,000 options of the Company, and the former CEO of Peace Naturals for approximately \$12,682 and a 10% equity interest in Peace Naturals, in connection with alleged claims of wrongful termination. Both plaintiffs have amended their pleadings to discontinue the claims against the individual directors. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend these claims; accordingly, no provision for loss has been recognized.

(c) The following contingency is related to Hortican:

- (i) *Illingworth Claim.* On March 9, 2018, Philip Illingworth (the “**Claimant**”) filed a claim in the Supreme Court of British Columbia against Evergreen, its directors, Welton Construction Limited, 0611389 B.C. Ltd. and Hortican, claiming among other things, declarations and an order for specific performance that the plaintiff is the owner of 50% of the shares of Evergreen. On June 20, 2018, the claim was discontinued by the Claimant against Hortican Inc.

21. Income taxes

The Company's combined Canadian federal and provincial statutory income tax rate is 26.5% for the three and six months ended June 30, 2018 and June 30, 2017. The rate is expected to apply for the full year and is applied to the pre-tax income of the three and six months.

Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset.

The changes in the net deferred tax liability are provided below:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Balance - beginning of period	\$ 555	\$ 1,458	\$ 1,416	\$ 1,457
Recognized in income	(267)	(23)	(1,155)	(22)
Recognized in other comprehensive income	(20)	-	7	-
Balance - end of period	<u>\$ 268</u>	<u>\$ 1,435</u>	<u>\$ 268</u>	<u>\$ 1,435</u>

Cronos Group Inc.**Notes to Unaudited Condensed Interim Consolidated Financial Statements****For the three and six month periods ended June 30, 2018 and June 30, 2017***(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)***22. Financial instruments****(i) Credit risk**

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's accounts receivable, promissory note receivable, and loan receivable. The maximum exposure to credit risk is the carrying value of these financial assets. The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. As at June 30, 2018 and December 31, 2017, there were no impairment losses recognized on the promissory note receivable, loan receivable, or receivables from contracts with customers.

As at June 30, 2018, the value of promissory note receivable was \$1,304 (December 31, 2017 - \$Nil), loan receivable was \$314 (December 31, 2017 - \$314), receivables from employees was \$429 (December 31, 2017 - \$Nil), and trade receivables was \$2,415 (December 31, 2017 - \$1,140). The Company is not significantly exposed to credit risk, as these receivables comprise 1.9% (December 31, 2017 - 1.4%) of the Company's total assets. As at June 30, 2018, 67.4% (December 31, 2017 - 89.3%) of the Company's trade receivables were due from 1 customer (December 31, 2017 - 2 customers).

The following represents an analysis of the age of trade receivables:

	As at June 30, 2018	As at December 31, 2017
Less than 30 days past billing date	\$ 1,872	\$ 1,020
31 to 60 days past billing date	253	85
61 to 90 days past billing date	-	35
Over 90 days past billing date	290	-
	<u>\$ 2,415</u>	<u>\$ 1,140</u>

(ii) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. The Company's funding is primarily provided in the form of capital raised through the issuance of shares and warrants.

The following represents an analysis of the age of trade accounts payable:

	As at June 30, 2018	As at December 31, 2017
Less than 30 days past billing date	\$ 492	\$ 6,725
31 to 60 days past billing date	295	113
61 to 90 days past billing date	113	66
Over 90 days past billing date	223	172
	<u>\$ 1,123</u>	<u>\$ 7,076</u>

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

(iii) Market risk

(1) Price risk

Price risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to price risk in divesting its investments, in that, unfavourable market conditions could result in dispositions of investments at less than favourable prices. Further, the revaluation of securities classified as fair value through other comprehensive income, this could result in significant write-downs of the Company's investments, which would have an adverse impact on the Company's financial position.

The Company manages price risk by having a portfolio of securities from multiple issuers, such that the Company is not singularly exposed to any one issuer. The Company has also set thresholds on purchases of investments over which the approval of the Board is required.

(2) Concentration risk

Concentration risk is the risk that any single investment or group thereof, has the potential to materially affect the operating results of the Company. The Company is exposed to this risk as all of its investments are currently within the medical marijuana industry. As such, the Company's financial results may be adversely affected by the unfavourable performance of those investments or the industry in which they operate.

(iii) Currency rate risk

Currency rate risk is the risk that changes in the relative value of Canadian dollars to other currencies will reduce the value of financial assets. The Company is exposed to this risk as the promissory note receivable, refer to Note 8, is denominated in Israeli Shekels. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk as management has determined that this risk is not significant at this point in time. As such, the Company's financial position and financial results may be adversely affected by the unfavourable fluctuations in currency exchange rates.

It is management's opinion that the Company is not subject to significant interest rate risk.

Cronos Group Inc.

Notes to Unaudited Condensed Interim Consolidated Financial Statements

For the three and six month periods ended June 30, 2018 and June 30, 2017

(in thousands of CDN \$, except where otherwise noted, and share, per share, weight, volume and plant amounts)

23. Fair value hierarchy

Assets recorded at fair value on the unaudited condensed interim consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities. In these unaudited condensed interim consolidated financial statements, cash and other investments (Canopy, Hydroponthecary, and ABCann shares) are included in this category.

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. In these unaudited condensed interim consolidated financial statements, ABCann share purchase warrants are included in this category.

Level 3 - valuation techniques using the inputs for the asset or liability that are not based on observable market data. In these unaudited condensed interim consolidated financial statements, other investments (Evergreen), and biological assets are included in this category.

The Company's policy for determining when transfers between levels of the fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer.

During the six months ended June 30, 2017, Hydroponthecary and ABCann became publicly traded. Due to these events, the investment in Hydroponthecary and ABCann were transferred out of Level 3 as the inputs for the valuation of the investment were no longer unobservable. The investment in Hydroponthecary and ABCann were transferred into Level 1 of the fair value hierarchy, as the valuations of the investments were based on quoted prices in an active market.

During the six months ended June 30, 2018, there were no transfers between levels.

24. Capital management

The Company's objectives when managing its capital are to maintain a sufficient capital base to: (i) meet its short-term obligations, (ii) sustain future operations and expansions, (iii) ensure its ability to continue as a going concern, and (iv) retain stakeholder confidence. The Company defines capital as its net assets, total assets less total liabilities. Currently, there are no quantitative criteria established as the Company is experiencing significant growth.

As at June 30, 2018, the Company managed net assets of \$227,270 (December 31, 2017 - \$86,368).

25. Subsequent events

- (a) Subsequent to June 30, 2018, a total of 4,466 options were exercised in exchange for \$11 in cash. These options had a weighted average exercise price of \$2.55 per common share. Also, subsequent to June 30, 2018, 1,900 share appreciation rights were exercised, in lieu of the associated options, in exchange for 1,266 common shares.
- (b) Subsequent to June 30, 2018, a total of 236,602 warrants were exercised in exchange for \$73 in cash. These warrants had a weighted average exercise price of \$0.31 per common share.
- (c) On July 18, 2018, the Company announced a strategic joint venture with a group of investors led by Bert Mucci (the "**Greenhouse Partners**"), a leading Canadian large-scale greenhouse operator. The Company and the Greenhouse Partners each owns a 50% equity interest in the joint venture, Cronos Growing Company Inc. ("**Cronos GrowCo**"), and have equal board representation on the board of directors of Cronos GrowCo. Cronos GrowCo is planning to construct an 850,000 sq. ft. purpose-built, GMP certified greenhouse for cannabis production on approximately 100 acres of land owned by Cronos GrowCo in Kingsville, Ontario. Once fully operational, the greenhouse is expected to produce up to 70,000 kilograms of cannabis annually.



CRONOS GROUP INC.

Management's Discussion and Analysis of Financial Condition and Results of Operations

For the Three and Six Months Ended June 30, 2018

(in thousands of Canadian dollars)

GENERAL MATTERS

This management's discussion and analysis of financial condition and results of operations ("MD&A") of Cronos Group Inc. is current as of August 13, 2018 and provides financial information for the three and six months ended June 30, 2018. This MD&A should be read in conjunction with the unaudited condensed interim consolidated financial statements for the three and six months ended June 30, 2018 and June 30, 2017, including the related notes thereto (the "Interim Financial Statements"), and the audited consolidated financial statements for the year ended December 31, 2017, including the related notes thereto and the related MD&A.

Unless otherwise noted or the context indicates otherwise, the "Company", "Cronos Group", "we", "us" and "our" refer to Cronos Group Inc., its direct and indirect subsidiaries and, if applicable, its joint ventures.

Our board of directors, on the recommendation of the audit committee, approved the Interim Financial Statements and this MD&A on August 13, 2018.

Basis of Presentation

Our financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). Certain totals, subtotals and percentages throughout this MD&A are calculated using the rounded numbers as they appear in the tables. All currency amounts herein are expressed in thousands of Canadian dollars, unless otherwise noted.

All references in this MD&A to "Q2 2018" and "Q2 2017" are to the fiscal quarters for the three months ended June 30, 2018 and June 30, 2017, respectively. All references in this MD&A to "YTD 2018" and "YTD 2017" are to the six months ended June 30, 2018 and June 30, 2017, respectively.

Definitions

Equivalent grams and kilograms

Equivalent grams or kilograms refers to the equivalent number of dried grams or kilograms of cannabis required to produce extracted cannabis in the form of cannabis oil. The Company estimates and converts its cannabis oil inventory to equivalent grams using a standard conversion ratio of the number of grams of dry flower used to produce the extracted cannabis products. Any reference to "grams" or "kilograms" in this MD&A includes both equivalent grams and dried grams, unless otherwise noted and identified as dried grams or equivalent grams for extracts.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This MD&A contains certain information that may constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively, "Forward-Looking Statements"), which are based upon the Company's current internal expectations, estimates, projections, assumptions and beliefs. All information contained herein that is not clearly historical in nature may constitute Forward-Looking Statements. In some cases, Forward-Looking Statements can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, expressions and phrases, including negative and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of historical fact. Forward-Looking Statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as at and for periods ended on certain dates and to present information about management's current expectations and plans relating to the future and the reader is cautioned that such statements may not be appropriate for any other purpose. Forward-Looking Statements in this MD&A include, but are not limited to, statements with respect to:

- the performance of our business and operations;
- our expectations regarding revenues, expenses and anticipated cash needs;
- our expectations regarding cash flow, liquidity and sources of funding;
- the intended expansion of our facilities, the costs and timing associated therewith and the receipt of approval from Health Canada to increase the maximum production limits and sales from the expanded facilities;
- the expected growth in our growing and production capacities;
- expectations with respect to future production costs;
- the expected methods to be used by us to distribute cannabis;
- the competitive conditions of the industry;
- the legalization of cannabis for recreational use in Canada, including federal and provincial regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such market when it is legalized;

- the legalization of the use of cannabis for medical or recreational use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets outside of Canada, if and when such use is legalized;
- laws and regulations and any amendments thereto applicable to the business;
- the ability of the Company to execute on its strategy and the anticipated benefits of such strategy;
- the competitive advantages and business strategies of the Company;
- the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis;
- the Company's future product offerings;
- the anticipated future gross margins of the Company's operations;
- expectations regarding the use of proceeds of equity financings;
- expectations regarding capital expenditures;
- accounting standards and estimates; and
- the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof.

Certain of the Forward-Looking Statements contained herein concerning the cannabis industry and our general expectations concerning the cannabis industry are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of this industry, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While we are not aware of any misstatement regarding any industry or government data presented herein or information presented herein that is based on such data, the cannabis industry involves risks and uncertainties that are subject to change based on various factors, which factors are described further below.

With respect to the Forward-Looking Statements contained in this MD&A, we have made assumptions regarding, among other things: (i) our ability to generate cash flow from operations and obtain necessary financing on acceptable terms; (ii) general economic, financial market, regulatory and political conditions in which we operate; (iii) the output from operations of Peace Naturals Project Inc. ("**Peace Naturals**"), Original BC Ltd. ("**OGBC**") and our joint ventures; (iv) consumer interest in our products; (v) competition; (vi) anticipated and unanticipated costs; (vii) government regulation of our activities and products and in the areas of taxation and environmental protection; (viii) the timely receipt of any required regulatory approvals; (ix) our ability to obtain qualified staff, equipment and services in a timely and cost efficient manner; (x) our ability to conduct operations in a safe, efficient and effective manner; and (xi) our construction plans and timeframe for completion of such plans.

By their nature, Forward-Looking Statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the Forward-Looking Statements in this MD&A. Such factors include, without limitation, those discussed in the "Risk and Uncertainties" section of this MD&A, and those discussed under the heading "Risk Factors" in our latest Annual Information Form ("**AIF**").

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements. Forward-Looking Statements are based upon certain material assumptions, including those listed above, that were applied in drawing a conclusion or making a forecast or projection, including management's perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances, including that the factors listed in the foregoing paragraph, collectively, are not expected to have a material impact on the Company. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

Forward-Looking Statements contained herein are made as of the date of this MD&A and are based on the beliefs, estimates, expectations and opinions of management on the date such Forward-Looking Statements are made. The Company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such Forward-Looking Statements, except as required by applicable law. The Forward-Looking Statements contained in this MD&A are expressly qualified in their entirety by this cautionary statement.

COMPANY OVERVIEW

General

Cronos Group is a geographically diversified and vertically integrated global cannabis company, with a presence across four continents, whose principal activities are the production and sale of cannabis in federally legal jurisdictions, including Canada and Germany. Currently, Cronos Group sells dried cannabis and cannabis oils through wholesale and direct-to-consumer channels under our medical cannabis brand, PEACE NATURALSTM. We operate two wholly-owned licensed producers of medical cannabis (“**Licensed Producers**”) pursuant to the provisions of the *Controlled Drugs and Substances Act* (Canada) (“**CDSA**”) and its relevant regulation, the *Access to Cannabis for Medical Purposes Regulations* (Canada) (“**ACMPR**”). Our Licensed Producers are Peace Naturals, which has production facilities near Stayner, Ontario, and OGBC, which has a production facility in Armstrong, British Columbia.

We have also entered into five strategic joint ventures, including in Israel and Australia, and hold minority interests in cannabis-related companies and Licensed Producers.

Cronos Group’s common shares are listed on the Nasdaq Global Market (“**NASDAQ**”) and on the Toronto Stock Exchange (“**TSX**”) under the symbol “**CRON**”.

Strategy

Cronos Group is committed to being one of the world’s leading global cannabis companies. In pursuing this goal, we seek to create value for shareholders by focusing on four core strategic priorities:

- establishing an efficient global production footprint;
- developing a diversified global sales and distribution network;
- creating and monetizing disruptive intellectual property; and
- growing a portfolio of iconic brands that resonate with consumers.

Production Facilities

Facility	Location	Grow Type	Square Footage	Estimated Annual Capacity (in kg)
Existing Capacity (1)				
Peace Naturals – Buildings 1, 2, 3	Stayner, ON, Canada	Indoor	39,000	5,000
Peace Naturals – Greenhouse	Stayner, ON, Canada	Greenhouse	28,000	1,500
OGBC	Armstrong, BC, Canada	Indoor	2,500	150
Existing Capacity			69,500	6,650
Capacity in Progress				
Peace Naturals – Building 4	Stayner, ON, Canada	Indoor	286,000	33,500
Cronos Israel – Phase I (2)	Hadera, Israel	Greenhouse	45,000	5,000
Cronos Australia – Phase I (3)	Melbourne, VIC, Australia	Indoor	20,000	2,000
Cronos GrowCo (4)	Kingsville, ON, Canada	Greenhouse	850,000	70,000
Capacity in Progress			1,201,000	110,500
Pro Forma Capacity			1,270,500	117,150

(1) Existing capacity is defined as facilities where construction is substantially complete, regulatory approvals required to commence operations have been received and cannabis cultivation has commenced.

(2) Cronos Group will hold a 70% equity interest in the nursery and cultivation operations of Cronos Israel (as defined herein) and a 90% equity interest in the manufacturing and distribution operations of Cronos Israel.

(3) Cronos Group owns a 50% equity interest in Cronos Australia (as defined herein).

(4) Cronos Group owns a 50% equity interest in Cronos GrowCo (as defined herein).

Peace Naturals

Situated on approximately 90 acres of land zoned and licensed for cannabis production, Peace Naturals operates four completed production buildings (Building 1, Building 2, Building 3 and the Peace Naturals greenhouse) and is constructing additional capacity via a 286,000 sq. ft. production facility (“**Building 4**”). Peace Naturals’ production processes are Good Manufacturing Practices (“**GMP**”) certified under relevant European Economic Area GMP directives by the national competent authority of Germany.

On October 31, 2013, Health Canada issued a license to Peace Naturals for activities related to the production and sale of dried cannabis flower under the ACMPR, which license has since been amended and supplemented. Peace Naturals’ current license has an effective

term from November 1, 2016 to November 1, 2019, and grants Peace Naturals the right to engage in, among other things, the production and sale of dried cannabis flower, cannabis resin, cannabis seeds, cannabis plants and cannabis oil.

On January 22, 2018, Peace Naturals received a dealer's license (the "**Peace Naturals Dealer's License**") pursuant to the Narcotic Control Regulations ("**NCR**") and CDSA from Health Canada for the possession, sale, transportation and delivery of controlled substances under the CDSA, including cannabis, tetrahydrocannabinol ("**THC**") and cannabidiol ("**CBD**"). The Peace Naturals Dealer's License allows Peace Naturals to export medical cannabis extracts, including concentrated oil and resin products, internationally, in accordance with an export permit issued under section 103 of the ACMPR or section 10 of the NCR. The Peace Naturals Dealer's License has an effective term from January 29, 2018 to December 31, 2018.

OGBC

Situated on 30 acres of land, 13 acres of which are zoned and licensed for cannabis production, OGBC's facility primarily engages in cultivation and processing operations. OGBC currently engages in inter-company bulk transfers of dried cannabis flower to Peace Naturals, which are sold under the PEACE NATURALSTM brand.

On February 26, 2014, Health Canada issued a cultivation license to OGBC under the ACMPR, which license has since been amended and supplemented. OGBC's current license has an effective term from February 28, 2017 to February 28, 2020 and grants OGBC the right to engage in the production and sale of dried cannabis flower.

Transition of Licenses under the Cannabis Act

As of October 17, 2018, we expect our Licensed Producers to be primarily regulated under the new Cannabis Act (Canada) and its relevant regulations (collectively, the "**Cannabis Act**"). While the exact transition requirements have not yet been announced by the Canadian federal government, the Cannabis Act does contain general transition provisions for licenses issued under the CDSA and its relevant regulations (including the ACMPR).

The Cannabis Act generally provides that licenses issued under the ACMPR that are in force immediately before the commencement date of the Cannabis Act will be deemed to be licenses issued under the corresponding provisions of the Cannabis Act and any such licenses will continue in force until it is revoked or expires. In particular, a license for production and sale of dried cannabis flower, cannabis resin, cannabis seeds, cannabis plants and cannabis oil under the ACMPR will be deemed to be licenses for cultivation, processing and sale for medical purposes under the Cannabis Act, provided that the license holder meets certain requirements. We expect the licenses under the ACMPR held by our Licensed Producers to be subject to these transition provisions.

Similarly, the Cannabis Act generally provides that licenses issued under the NCR that are in force immediately before the commencement date of the Cannabis Act will be deemed to be licenses issued under the corresponding provisions of the Cannabis Act and any such licenses will continue in force until it is revoked or expires. In particular, a license for possession, sale, transportation and delivery of cannabis, THC and CBD under the NCR will be deemed to be a license for processing under the Cannabis Act. We expect the Peace Naturals Dealer's License to be subject to these transition provisions.

The Cannabis Act also contains transition provisions that generally provide that an export permit issued under section 103 of the ACMPR or section 10 of the NCR relating to cannabis that is in force immediately before the commencement date of the Cannabis Act will be deemed to be a permit issued under the corresponding provision of the Cannabis Act and any such license will continue in force until it is revoked or expires. Under the Cannabis Act, licenses and permits authorizing the importation or exportation of cannabis may be issued only in respect of cannabis for medical or scientific purposes or in respect of industrial hemp.

Joint Ventures

We have entered into five strategic joint ventures to produce and sell cannabis:

- *Cronos GrowCo Joint Venture.* In July 2018, the Company announced a strategic joint venture with a group of investors led by Bert Mucci (the "**Greenhouse Partners**"), a leading Canadian large-scale greenhouse operator. The Company and the Greenhouse Partners each owns a 50% equity interest in the joint venture, Cronos Growing Company Inc. ("**Cronos GrowCo**"), and have equal representation on the board of directors of Cronos GrowCo. Cronos GrowCo is planning to construct an 850,000 sq. ft. purpose-built, GMP certified greenhouse for cannabis production on approximately 100 acres of land owned by Cronos GrowCo in Kingsville, Ontario. Once fully operational, the greenhouse is expected to produce up to 70,000 kilograms of cannabis annually.
- *MedMen Canada Joint Venture.* In March 2018, the Company entered into a strategic joint venture with MedMen Enterprises USA, LLC ("**MedMen**"). The Company and MedMen each owns a 50% equity interest in the joint venture, MedMen Canada Inc. ("**MedMen Canada**"), and have equal representation on the board of directors of MedMen Canada. MedMen Canada holds the exclusive license of the MedMen brand in Canada for a minimum term of 20 years. MedMen Canada is currently in the process of obtaining the necessary licenses, permits and retail locations to create a premium MedMen branded retail chain, modelled after its

iconic retail concept in Los Angeles, Las Vegas and Manhattan, in provinces where private retail is allowed including British Columbia and Alberta.

- *Australia Joint Venture.* In February 2018, the Company entered into a strategic joint venture in Australia with NewSouthern Capital Pty Ltd. (“**NewSouthern**”) for the research, production, manufacture and distribution of medical cannabis. The Company and NewSouthern each owns a 50% equity interest in the joint venture, Cronos Australia Pty Ltd. (“**Cronos Australia**”) and have equal representation on the board of directors of Cronos Australia. The Company believes that Cronos Australia will serve as its hub for Australia, New Zealand and Southeast Asia, bolstering the Company’s supply capabilities and distribution network. In the initial phase of construction, Cronos Australia is planning to construct a 20,000 sq. ft. purpose-built indoor facility that is expected to produce up to 2,000 kilograms of cannabis annually. Cronos Australia has also been granted a medicinal cannabis cultivation license, a research license and a manufacturing license by the Therapeutic Goods Administration and the Office of Drug Control (the “**ODC**”). Cronos Australia has also applied for an import license to import PEACE NATURALS™ branded medical products for sale in the Australian market while the initial phase of construction of Cronos Australia is being completed. Cronos Australia is awaiting the approval of the ODC for the import license.
- *Israel Joint Venture.* In September 2017, the Company entered into a strategic joint venture (“**Cronos Israel**”) in Israel with the Israeli agricultural collective settlement Kibbutz Gan Shmuel (“**Gan Shmuel**”) for the production, manufacture and distribution of medical cannabis. Following transfer of the Israeli licenses from Gan Shmuel to Cronos Israel and receipt of approval from the Israeli Ministry of Health, the Company will hold a 70% interest in each of the nursery and cultivation operations and a 90% interest in each of the manufacturing and distribution operations. The Israeli licenses were successfully transferred to Cronos Israel on May 10, 2018 and the equity interests are expected to be issued to Cronos Group shortly after the Israeli Ministry of Health approves the issuance of the equity interests. Cronos Group will have three board member nominees on the board of directors of each of the cultivation, manufacturing, distribution and pharmacies companies, while Gan Shmuel will have one board member nominee on the board of directors of each such entity. In the initial phase of construction, Cronos Israel is planning to construct a 45,000 sq. ft. greenhouse that is expected to produce up to 5,000 kilograms of cannabis annually and a 17,000 sq. ft. manufacturing facility that will be utilized for analytics, formulation development and research. Until exports are permitted under applicable Israeli law, products from Cronos Israel will be distributed domestically in the local Israeli market.
- *Indigenous Roots Joint Venture (“**Indigenous Roots**”).* In December 2016, the Company launched a strategic joint venture led by Phil Fontaine, former National Chief of the Assembly of First Nations. Indigenous Roots will work cooperatively with Canadian First Nations towards building and operating licensed facilities and providing medical cannabis to First Nations communities in Canada. We will own a 49.9% stake in Indigenous Roots upon closing of the investment, which is expected to be led by a First Nation. The Company believes that Indigenous Roots will provide Cronos Group with optionality for nontraditional distribution channels, incremental production capacity without dilution and a strong brand for our portfolio. Indigenous Roots has commanded significant interest, having met with over 100 indigenous communities and leaders across Canada. Indigenous Roots is in the process of finalizing its capital raise. Once completed, Indigenous Roots is anticipated to commence construction of a 30,000 sq. ft. production facility at the premises of OGBC. The Company is awaiting definitive regulatory clarity on provincial distribution frameworks prior to finalization of the capital raise.

Minority Investments

We hold minority interests in other Licensed Producers. As at June 30, 2018, the Company held a 19.0% equity interest in Whistler Medical Marijuana Corporation (“**Whistler**”) and minority equity investments in Evergreen Medicinal Supply Inc. (“**Evergreen**”) and Canopy Growth Corporation (“**Canopy**”).

INDUSTRY AND MARKET TRENDS

Medical Cannabis Regulatory Framework in Canada

On August 24, 2016, the Government of Canada introduced the ACMPR regulations to govern the production, sale and distribution of medical cannabis and related oil extracts. The ACMPR effectively combines the regulations and requirements of the *Marihuana for Medical Purposes Regulations*, the *Marihuana Medical Access Regulations* and the section 56 exemptions relating to cannabis oil under the CDSA into one set of regulations. In addition, among other things, the ACMPR sets out the process patients are required to follow to obtain authorization from Health Canada to grow cannabis and to acquire seeds or plants from Licensed Producers to grow their own cannabis. Under the ACMPR, patients have three options for obtaining cannabis:

- they can continue to access quality-controlled cannabis by registering with Licensed Producers;
- they can register with Health Canada to produce a limited amount of cannabis for their own medical purposes; or
- they can designate someone else to produce it for them.

Legalization of Regulated Recreational Cannabis in Canada

On December 13, 2016, the Task Force on Cannabis Legalization and Regulation, which was established by the Canadian federal government to seek input on the design of a new system to legalize, strictly regulate and restrict access to cannabis, published its report outlining its recommendations. On April 13, 2017, the Government of Canada released Bill C-45, *An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts* (“**Bill C-45**”), which proposed the enactment of the Cannabis Act to regulate the production, distribution and sale of cannabis for medical and unqualified adult use. After significant debates at the House of Commons and the Senate, on June 21, 2018, Bill C-45 received Royal Assent. On July 11, 2018, the Government of Canada published the final regulations under the Cannabis Act. These regulations provide more details on the medical and recreational regulatory regimes for cannabis, including regarding licensing, security clearances and physical security requirements, production practices, outdoor growing, security, packaging and labelling, cannabis containing drugs, document retention requirements, reporting and disclosure requirements, the new access to cannabis for medical purposes regime and industrial hemp.

The Prime Minister of Canada has communicated that the majority of the Cannabis Act will come into force on October 17, 2018. The delay in the coming into force date is to provide enough time for the implementation of various aspects of the regime, including preparing markets for retail sales.

The introduction of a recreational regulatory framework for cannabis production and distribution would be a significant new market for the Company’s product. However, it is still uncertain how these developments may impact the medical cannabis market. The impacts may also be negative for the Company and could result in increased levels of competition in its existing medical market and / or the entry of new competitors in the overall cannabis market in which the Company operates.

Provincial Distribution Frameworks for Regulated Recreational Cannabis

While the Cannabis Act provides for the regulation of the commercial production of cannabis for medical and recreational purposes and related matters by the federal government, the provinces and territories of Canada will have authority to regulate other aspects of recreational cannabis (similar to what is currently the case for liquor and tobacco products), such as sale and distribution, minimum age requirements, places where cannabis can be consumed, and a range of other matters. The governments of every Canadian province and territory have announced proposed regulatory regimes for the distribution and sale of cannabis for recreational purposes within those jurisdictions.

QUARTERLY BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS POST QUARTER-END

Revenue increased 428% in Q2 2018 as compared to Q2 2017

Revenue increased by \$2.8 million, or 428%, from \$0.6 million in Q2 2017 to \$3.4 million in Q2 2018. Additionally, the Company continues to see strong growth in cannabis oil sales largely due to its increased supply of a broader assortment of cannabis oils that have been received favorably by customers. In Q2 2018, cannabis oil sales accounted for 40% of domestic medical sales as compared to 29% in Q1 2018.

Establishing an efficient global production footprint

Cronos GrowCo

In July 2018, we announced a strategic joint venture with the Greenhouse Partners, a leading Canadian large-scale greenhouse operator. The Company and the Greenhouse Partners each owns a 50% equity interest in the joint venture, Cronos GrowCo, and have equal representation on the board of directors of Cronos GrowCo. Cronos GrowCo is planning to construct an 850,000 sq. ft. purpose-built, GMP certified greenhouse for cannabis production on approximately 100 acres of land owned by Cronos GrowCo in Kingsville, Ontario. Once fully operational, the greenhouse is expected to produce up to 70,000 kilograms of cannabis annually. Greenhouse construction materials are currently on the production site and construction is expected to commence this summer.

Cronos Australia receives manufacture license

Cronos Australia was granted a medicinal cannabis manufacture license by the Australian ODC in June 2018. This license permits manufacturing of cannabinoid based products in Australia and is required for all forms of extraction, refining, concentration and transformation of the cannabis plant. This license rounds out the licenses for domestic production, which includes the medicinal cannabis cultivation license and research license and brings Cronos Group one step closer to full scale operations in Australia.

Continued progress on capacity expansion projects

- *Building 4.* Construction of Building 4, a 286,000 sq. ft. custom-built indoor production facility built to GMP standards, remains on schedule and cultivation is expected to commence in the second half of 2018.
- *Cronos Israel.* Construction of the custom-built greenhouse and manufacturing facility, each built to GMP standards, has begun. Given modification to facility designs to provide greater flexibility in the cultivation and manufacture of different end products, the expected completion date of construction has changed from Q1 2019 to the first half of 2019 for the greenhouse and to the second half of 2019 for the manufacturing facility. Cultivation is expected to commence in the first half of 2019.

- *Cronos Australia.* The Company is currently in the design and construction planning phase for the custom-built production facility built to GMP standards. We expect construction to commence in the summer of 2018 and to be complete in the first half of 2019.

Developing a diversified global sales and distribution network

Cura supply agreement

In August 2018, Cronos Group announced a supply agreement with Cura Cannabis Solutions (“**Cura**”), one of the largest cannabis companies in the world by revenues in the first quarter of 2018. Cura signed a five year take-or-pay supply agreement to purchase a minimum of 20,000 kilograms of cannabis per annum from Cronos GrowCo, starting from the date Cura receives its production and sales licenses from Health Canada. Cura also expects to build its proprietary, state-of-the-art extraction facility on a parcel of land owned by Cronos Group in the heart of Okanagan Valley, British Columbia.

Distribution in Poland

In June 2018, we entered into a strategic distribution partnership with Delfarma Sp. Zo.o (“**Delfarma**”). Delfarma is a pharmaceutical wholesaler with a distribution network of over 5,000 pharmacies and more than 200 hospitals that collectively reaches approximately 40% of the Polish domestic market. Under the five-year exclusive distribution agreement, Cronos Group will supply PEACE NATURALS™ branded cannabis products to Delfarma for distribution within Poland. The Company and Delfarma are currently in the process of obtaining the necessary regulatory approvals to sell cannabis products in Poland.

Growing a portfolio of iconic brands that resonate with consumers

First recreational brand COVE™

Cronos Group previewed its premium recreational brand COVE™ at the May 2018 LIFT Conference. The newly launched brand, COVE™ was born in the Okanagan Valley in British Columbia, which is known for producing some of the world’s finest cannabis. COVE™ products are non-irradiated and hand-trimmed using only the best result of each harvest. By avoiding shortcuts like harsh refining processes, COVE™ is able to maintain the natural balance of the plant across all of the brand’s terpene rich cannabis extracts and brings the highest in quality products to its consumers.

Uplisting to the Toronto Stock Exchange

On May 23, 2018, the trading of the Company’s common shares in Canada were uplisted from the TSX Venture Exchange to the TSX. Cronos Group’s common shares are listed under the symbol “CRON” on both NASDAQ and TSX.

Appointment of KPMG LLP as auditor

In May 2018, the board of directors approved the appointment of KPMG LLP as auditor of the Company, which was subsequently approved by a majority of votes cast by shareholders at the Company’s Annual and Special Meeting of Shareholders on June 28, 2018.

Enhanced board of directors with the election of Michael Coates

Michael Coates was elected to the board of directors by a majority of votes cast by shareholders at the Company’s Annual and Special Meeting of Shareholders held on June 28, 2018. Michael Coates was President and Chief Executive Officer, Americas Region of Hill+Knowlton Strategies (“**H+K**”), a global public relations and integrated communications agency, from 2014 to 2016 and retired as Global Vice Chairman of H+K in 2017. Prior to this, Mr. Coates held a variety of roles at H+K and has had a more than thirty-year career advising Fortune 500 clients on strategies to manage political risk. In June 2018, Michael served as a member of the Premier of Ontario’s transition team. Mr. Coates received an MPA from Queen’s University and holds an ICD.D designation from the Institute of Corporate Directors.

Strengthened liquidity with a \$100.0 million equity offering in April 2018

The Company closed a bought deal offering of common shares in April 2018 (the “**April 2018 Bought Deal**”) that provided aggregate gross proceeds of \$100.0 million (not taking into account any commissions, fees or expenses). As of June 30, 2018, total liquidity amounted to \$118.3 million, comprised of \$89.6 million in cash and \$28.7 million of additional borrowings available under the Construction Loan (as defined herein).

RESULTS OF OPERATIONS

Selected Financial Results

The following table summarizes the selected financial results for the periods indicated.

(\$ in 000s)

	Three Months Ended				Six Months Ended			
	June 30,		Change		June 30,		Change	
	2018	2017	\$	%	2018	2017	\$	%
Revenue	\$ 3,394	\$ 643	\$ 2,751	428%	\$ 6,339	\$ 1,157	\$ 5,182	448%
Cost of Sales	(2,952)	(478)	(2,474)	518%	(1,935)	(1,000)	(935)	94%
Gross Profit	6,346	1,121	5,225	466%	8,274	2,157	6,117	284%
Operating Expenses	5,856	2,626	3,230	123%	9,962	4,399	5,563	126%
Operating Income (Loss)	490	(1,505)	1,995	(133%)	(1,688)	(2,242)	554	(25%)
Other Income (Expense)	(34)	1,656	(1,690)	(102%)	206	1,550	(1,344)	(87%)
Income (Loss) before Income Taxes	456	151	305	202%	(1,482)	(692)	(790)	114%
Income Tax Recovery	(267)	(23)	(244)	1061%	(1,155)	(22)	(1,133)	5150%
Net Income (Loss)	723	174	549	316%	(327)	(670)	343	(51%)
Other Comprehensive Income	39	11	28	255%	4	694	(690)	(99%)
Comprehensive Income (Loss)	762	185	577	312%	(323)	24	(347)	(1446%)

Revenue

The following table sets forth revenue, kilograms sold and average sales price per gram by product type for the periods indicated.

(\$ in 000s)

	Three Months Ended June 30, 2018			Six Months Ended June 30, 2018		
	Revenue	Kilograms	Avg. Sales	Revenue	Kilograms	Avg. Sales
		Sold	Price / Gram		Sold	Price / Gram
Dry Cannabis	\$ 2,715	416	\$ 6.53	\$ 5,335	894	\$ 5.97
Cannabis Oil	636	61	10.43	891	84	10.61
Other	43	—	—	113	—	—
Total	3,394	477	7.12	6,339	978	6.48

Results for Q2 2018 compared to Q2 2017

For Q2 2018, the Company reported revenue of \$3.4 million as compared to \$0.6 million for Q2 2017, representing an increase of \$2.8 million, or 428%. This change was primarily due to:

- continued expansion in our patient onboarding as domestic medical patient sales grew 234% year-over-year;
- expanded production with an increase of 489% in the number of grams of cannabis sold year-over-year; and
- continued strong growth in our cannabis oil sales that represent 40% of domestic medical revenue in the current quarter.

During Q2 2018, 477 kilograms of cannabis products were sold at an average selling price of \$7.12 per gram. This represents an increase in volume of 396 kilograms sold compared to the Q2 2017 at an average selling price of \$7.99 per gram.

Results for YTD 2018 compared to YTD 2017

For YTD 2018, the Company reported revenue of \$6.3 million as compared to \$1.2 million for YTD 2017, representing an increase of \$5.2 million, or 448%. This change was primarily due to:

- expansion in our patient onboarding;
- launch and strong growth in our cannabis oils sales; and
- increased production capacity and yield developments.

During YTD 2018, 978 kilograms of cannabis products were sold at an average selling price of \$6.48 per gram. This represents an increase in volume of 832 kilograms sold compared to YTD 2017 at an average selling price of \$7.93 per gram.

Cost of Sales and Gross Profit

Cost of sales and gross profit for the periods indicated are as follows:

(\$ in 000s)

	Three Months Ended June 30,		Change		Six Months Ended June 30,		Change	
	2018	2017	\$	%	2018	2017	\$	%
Cost of Sales								
Inventory Expensed to Cost of Sales before Fair Value Adjustments	\$ 1,254	\$ 215	\$ 1,039	483%	\$ 2,821	\$ 413	\$ 2,408	583%
Gross Profit before Fair Value Adjustments	2,140	428	1,712	400%	3,518	744	2,774	373%
Fair Value Adjustments								
Unrealized Change in Fair Value of Biological Assets	(6,831)	(1,122)	(5,709)	509%	(9,575)	(2,701)	(6,874)	254%
Realized Fair Value Adjustments on Inventory Sold	2,625	429	2,196	512%	4,819	1,288	3,531	274%
Total Fair Value Adjustments	(4,206)	(693)	(3,513)	507%	(4,756)	(1,413)	(3,343)	237%
Gross Profit	6,346	1,121	5,225	466%	8,274	2,157	6,117	284%
<i>Gross Margin Before Fair Value Adjustments</i>	63%	67%			55%	64%		
<i>Gross Margin</i>	187%	174%			131%	186%		

Results for Q2 2018 compared to Q2 2017

Total cost of sales was a recovery of \$3.0 million in Q2 2018 as compared to a recovery of \$0.5 million in Q2 2017, representing a decrease in expenses of \$2.5 million. This change is largely driven by:

- an increase in the number of kilograms sold during the period;
- an increase in growing costs relating to addition of new production facilities, such as the Peace Naturals Greenhouse; and
- offset by overall lower growing costs on a per gram basis.

Inventory expensed to cost of sales before fair value adjustments represents the actual growing and processing costs associated with cannabis sold during the period, including labor, material, consumables, supplies, utilities, overhead allocation, and amortization of production equipment and facilities.

During Q2 2018, the Company made a voluntary change in accounting policy to capitalize the direct and indirect costs attributable to the biological asset transformation. The previous accounting policy was to expense these costs as period costs identified as Production Costs. The new accounting policy provides more reliable and relevant information to users as the gross profit before fair value adjustments only considers the costs incurred on inventory sold during the period, and excludes costs incurred on the biological transformation until the related harvest is sold. This accounting policy change does not impact gross profit, net income (loss), basic or diluted earnings per share, the statement of financial position, or the statement of changes in equity on the current or prior periods.

In Q2 2018, inventory expensed to costs of sales before fair value adjustments of \$1.2 million on sales of \$3.4 million, results in a gross profit before fair value adjustments of \$2.1 million, or 63% gross margin on 477 kilograms sold, as compared to inventory expensed to costs of sales before fair value adjustments of \$0.2 million on sales of \$0.6 million, results in a gross profit before fair value adjustments of \$0.4 million, or 67% gross margin on 80 kilograms sold during Q2 2017. Management anticipates the cost to produce dry cannabis will continue to decrease as production output increases now that Buildings 1, 2, 3 and the Peace Naturals greenhouse are fully operational. Operational costs in Q2 2018 included expenditures related to the Peace Naturals greenhouse, however no product was harvested from the greenhouse during this period.

Fair value adjustments of a recovery of \$4.2 million in Q2 2018, as compared to a recovery of \$0.7 million in Q2 2017 representing an increase of \$3.5 million. The fair value adjustments consist of: i) unrealized change in fair value of biological assets of \$6.8 million recovery in Q2 2018, compared to \$1.1 million recovery in Q2 2017, and ii) realized fair value adjustments on inventory sold in the period of \$2.6 million cost, compared to \$0.4 million cost in Q2 2017. The change in fair value adjustments is largely driven by:

- larger number of plants under cultivation; and
- partially offset by an increase in growing costs associated with more cultivation rooms including growing costs relating to the Peace Naturals greenhouse which recently came on line but had no harvested product during the period.

The cost to produce dry cannabis per gram is used by management to measure the estimated amount of growing costs (including all direct and indirect growing costs, overhead allocation, and amortization associated with the cultivation of cannabis) on a per gram basis, that are required to produce dry cannabis during the reporting period. Management uses this measure to track growing cost trends by using the total estimated growing costs (excluding all post-harvest production costs), and dividing such amount by the approximate

number of grams of cannabis grown during the period. Post-harvest production costs include drying and curing direct expenses, quality control and testing expenses, shipping and packaging expenses, and other order fulfillment costs.

In Q2 2018, total growing costs were \$1.8 million, including \$0.1 million of amortization associated with the growing equipment and facilities, and 1,145 kilograms were grown during the quarter, resulting in an all-in cost to produce dry cannabis of \$1.64 per gram, and \$1.52 per gram on a cash basis after backing out amortization. In Q1 2018, the all-in cost to produce dry cannabis was \$2.18 per gram.

Gross profit including fair value adjustments for Q2 2018 of \$6.3 million or 187% of sales, as compared to \$1.1 million or 174% of sales for Q2 2017, represents an increase of \$5.2 million. Gross profit increased during the quarter primarily due to the increase in sales and an increase in fair value gains driven by increased production capacity, yield improvements, and increased portion of cannabis oil sales.

Results for YTD 2018 compared to YTD 2017

Total cost of sales was a recovery of \$1.9 million in YTD 2018 as compared to a recovery of \$1.0 million in YTD 2017, representing a decrease in expenses of \$0.9 million. This change is largely driven by:

- an increase in the number of kilograms sold during the period;
- an increase in growing costs relating to addition of new production facilities, such as the Peace Naturals Greenhouse; and
- offset by overall lower growing costs on a per gram basis.

Inventory expensed to cost of sales before fair value adjustments represents the actual growing and processing costs associated with cannabis sold during the period, including labor, material, consumables, supplies, utilities, overhead allocation, and amortization of production equipment and facilities.

In YTD 2018, inventory expensed to costs of sales before fair value adjustments of \$2.8 million on sales of \$6.3 million, results in a gross profit before fair value adjustments of \$3.5 million, or 55% gross margin on 978 kilograms sold, as compared to inventory expensed to costs of sales before fair value adjustments of \$0.4 million on sales of \$1.2 million, results in a gross profit before fair value adjustments of \$0.7 million, or 64% gross margin on 146 kilograms sold during YTD 2017.

Fair value adjustments of a recovery of \$4.7 million in YTD 2018, as compared to a recovery of \$1.4 million in YTD 2017 representing an increase of \$3.3 million. The fair value adjustments consist of: i) unrealized change in fair value of biological assets of \$9.6 million recovery in YTD 2018, compared to \$2.7 million recovery in YTD 2017 and ii) realized fair value adjustments on inventory sold in the period of \$4.8 million cost, compared to \$1.3 million cost in YTD 2017. The change in fair value adjustments is largely driven by:

- larger number of plants under cultivation; and
- partially offset by an increase in growing costs associated with more cultivation rooms including growing costs relating to the Peace Naturals greenhouse which recently came on line but had no harvested product during the period.

In YTD 2018, total growing costs were \$3.5 million, including \$0.3 million of amortization associated with the growing equipment and facilities, and 1,861 kilograms were grown during the period, resulting in an all-in cost to produce dry cannabis of \$1.88 per gram, and \$1.72 per gram on a cash basis after backing out amortization.

Gross profit including fair value adjustments for YTD 2018 of \$8.3 million or 131% of sales, as compared to \$2.2 million or 186% of sales for YTD 2017, represents an increase of \$6.1 million. Gross profit increased during the period primarily due to the increase in sales and an increase in fair value gains driven by increased production capacity, yield improvements, and increased portion of cannabis oil sales.

Operating Expenses

Operating expenses for the periods indicated are as follows:

	Three Months Ended				Six Months Ended			
	June 30,		Change		June 30,		Change	
	2018	2017	\$	%	2018	2017	\$	%
Operating Expenses								
Sales and Marketing	\$ 364	\$ 87	\$ 277	318%	\$ 950	\$ 131	\$ 819	625%
General and Administrative	4,219	1,872	2,347	125%	6,680	3,208	3,472	108%
Share-Based Payments	950	439	511	116%	1,724	631	1,093	173%
Depreciation and Amortization	323	228	95	42%	608	429	179	42%
Total Operating Expenses	5,856	2,626	3,230	123%	9,962	4,399	5,563	126%
<i>As a Percentage of Revenue</i>								
Sales and Marketing	11%	14%			15%	11%		
General and Administrative	124%	291%			105%	277%		
Share-Based Payments	28%	68%			27%	55%		
Depreciation and Amortization	10%	35%			10%	37%		
Total Operating Expenses	173%	408%			157%	380%		

Results for Q2 2018 compared to Q2 2017

For Q2 2018, the Company reported total operating expenses of \$5.9 million as compared to \$2.6 million for Q2 2017, representing an increase of \$3.2 million, or 123%. This change was primarily due to:

- an increase in professional and consulting fees for services rendered in connection with various strategic initiatives and strengthening the company's governance and internal controls associated with the Company's NASDAQ listing;
- hiring of new employees and bringing on new dedicated functions such as procurement, information technology and investor relations;
- increase in stock-based compensation associated with stock options issued to employees, directors and service providers; and
- increase in depreciation expense allocated to operating expenses, the remainder of which is allocated to growing costs and capitalized to inventory.

Results for YTD 2018 compared to YTD 2017

For YTD 2018, the Company reported total operating expenses of \$10.0 million as compared to \$4.4 million for YTD 2017, representing an increase of \$5.6 million, or 126%. This change was primarily due to:

- an increase in professional and consulting fees for services rendered in connection with various strategic initiatives, expenditures associated with the Company's NASDAQ listing, and strengthening the company's governance and internal controls environment;
- an increase in payroll associated with building out existing and new functions; and
- increased amortization and stock-based compensation.

Other Income (Expense)

Other income (expense) for the periods indicated are as follows:

	Three Months Ended				Six Months Ended			
	June 30,		Change		June 30,		Change	
	2018	2017	\$	%	2018	2017	\$	%
Other Income (Expense)								
Interest Income (Expense)	\$ (37)	\$ 13	\$ (50)	(385%)	\$ (59)	\$ (137)	\$ 78	(57%)
Share of Income from Whistler Investment	3	313	(310)	(99%)	44	416	(372)	(89%)
Gain on Other Investments	—	1,330	(1,330)	(100%)	221	1,271	(1,050)	(83%)
Total Other Income (Expense)	(34)	1,656	(1,690)	(102%)	206	1,550	(1,344)	(87%)

Results for Q2 2018 compared to Q2 2017

For Q2 2018, the Company reported total other expense of \$0.03 million as compared to total other income of \$1.7 million for Q2 2017, representing a decrease in income of \$1.7 million, or 102%. This change was primarily due to an increase in the gain on other investments in the prior year quarter, as no investments were disposed during this quarter. Total other expense for Q2 2018 was attributable to interest expense during the quarter.

Results for YTD 2018 compared to YTD 2017

For YTD 2018, the Company reported total other income of \$0.2 million as compared to total other income of \$1.6 million for YTD 2017, representing a decrease in income of \$1.3 million, or 87%. This change was primarily due to a decrease in the gain on other investments, as investments were disposed during the previous year's quarter. This resulted in the gain on disposal and the previously recorded revaluation gains in other comprehensive income being recycled through net income.

Income Tax Recovery

Results for Q2 2018 compared to Q2 2017

The Company recorded an income tax recovery of \$0.3 million in Q2 2018 as compared to an income tax recovery of \$0.02 million in Q2 2017. The effective tax rate for Q2 2018 was (59%) as compared to (15%) in Q2 2017. The change in effective tax rate in Q2 2018 is mainly attributable to an increase in deductible temporary differences not recognized, specifically for property, plant, and equipment, share and debt issuance costs, and losses carried forward.

Results for YTD 2018 compared to YTD 2017

The Company recorded an income tax recovery of \$1.2 million in YTD 2018 as compared to an income tax recovery of \$0.02 million in YTD 2017. The effective tax rate for YTD 2018 was 78% as compared to 3% in YTD 2017. The change in effective tax rate in YTD 2018 is mainly attributable to an increase in deductible temporary differences not recognized, specifically for property, plant, and equipment, share and debt issuance costs, and losses carried forward.

Other Comprehensive Income

Other comprehensive income for the periods indicated are as follows:

(\$ in 000s)

	Three Months Ended		Change		Six Months Ended		Change	
	June 30,				June 30,			
	2018	2017	\$	%	2018	2017	\$	%
Other Comprehensive Income	\$ 39	\$ 11	\$ 28	255%	\$ 4	\$ 694	\$ (690)	(99%)

Results for Q2 2018 compared to Q2 2017

For Q2 2018, the Company reported no material change in other comprehensive income as compared to Q2 2017.

Results for YTD 2018 compared to YTD 2017

For YTD 2018, the Company reported other comprehensive income of \$0.004 million as compared to \$0.7 million for YTD 2017, representing a decrease of \$0.7 million, or 99%. This change was primarily due to the disposition of investments classified as fair value through other comprehensive income. The gain on revaluation of other investments represents only the revaluation of investments held by the Company as at June 30, 2018, which only includes the shares held in Canopy. The remainder of the investments were sold prior to YTD 2018, and thus, there would be no amount in this component of other comprehensive income related to those investments.

Comprehensive Income (Loss)

Comprehensive income (loss) for the periods indicated are as follows:

(\$ in 000s)

	Three Months Ended		Change		Six Months Ended		Change	
	June 30,				June 30,			
	2018	2017	\$	%	2018	2017	\$	%
Comprehensive Income (Loss)	\$ 762	\$ 185	\$ 577	312%	\$ (323)	\$ 24	\$ (347)	(1446%)

Results for Q2 2018 compared to Q2 2017

For Q2 2018, the Company reported comprehensive income of \$0.8 million as compared to income of \$0.2 million for Q2 2017, representing an increase of \$0.6 million. The change in total comprehensive income results from the factors described in the immediately preceding section above.

Results for YTD 2018 compared to YTD 2017

For YTD 2018, the Company reported comprehensive loss of \$0.3 million as compared to income of \$0.02 million for YTD 2017, representing a decrease of \$0.3 million. The change in total comprehensive income results from the factors described in the immediately preceding section above.

SELECTED QUARTERLY FINANCIAL INFORMATION

The following table summarizes selected quarterly financial information for the last eight quarters.

(\$ in 000s, except per share data)

	FY 2018		FY 2017				FY 2016	
	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3
Sales	\$ 3,394	\$ 2,945	\$ 1,610	\$ 1,314	\$ 644	\$ 514	\$ 431	\$ 124
Net Income (Loss)	723	(1,050)	2,063	1,097	175	(844)	1,370	(228)
Total Comprehensive Income (Loss)	762	(1,085)	2,025	1,095	187	(161)	2,737	(10)
Basic Earnings Per Share	\$ —	\$ (0.01)	\$ 0.01	\$ 0.01	\$ —	\$ (0.01)	\$ 0.01	\$ —
Diluted Earnings Per Share	—	(0.01)	0.01	0.01	—	(0.01)	0.01	—

The Company does not exhibit any material seasonality over its fiscal year. For further information on changes in income statement data, please see “Results of Operations” in this MD&A.

LIQUIDITY AND CAPITAL RESOURCES

Our principal sources of liquidity are cash, availability under the Construction Loan (as defined herein) and proceeds from capital financings. As of June 30, 2018, total liquidity amounted to \$118.3 million, comprised of \$89.6 million in cash and \$28.7 million of additional borrowings available under the Construction Loan (as defined herein).

Summary of Cash Flows

Our cash flows for the periods indicated are as follows:

(\$ in 000s)

	Three Months Ended			Six Months Ended		
	June 30,			June 30,		
	2018	2017	\$ Change	2018	2017	\$ Change
Cash used in Operating Activities	\$ (6,866)	\$ (3,328)	\$ (3,538)	\$ (20,629)	\$ (5,254)	\$ (15,375)
Cash used in Investing Activities	(30,161)	(3,903)	(26,258)	(38,286)	(7,149)	(31,137)
Cash provided by Financing Activities	94,268	(3,570)	97,838	139,316	13,345	125,971
Net Change in Cash	57,241	(10,801)	68,042	80,401	942	79,459

Analysis of Q2 2018 Cash Flows

Operating Activities. During Q2 2018, the Company used \$6.9 million of cash in operating activities as compared to \$3.3 million in Q2 2017, representing an increase of \$3.5 million. This change is primarily driven by a \$0.7 million decrease in net income adjusted for non-cash items and a \$2.8 million decrease in the net change in non-cash working capital from (\$1.8 million) in Q2 2017 to (\$4.6 million) in Q2 2018.

Investing Activities. During Q2 2018, the Company used \$30.2 million of cash in investing activities, primarily due to \$30.0 million in capital expenditures related to Building 4 construction activities.

Financing Activities. During Q2 2018, cash provided by financing activities was \$94.3 million, primarily due to \$93.7 million in net proceeds from the April 2018 Bought Deal.

Analysis of YTD 2018 Cash Flows

Operating Activities. During YTD 2018, the Company used \$20.6 million of cash in operating activities as compared to \$5.3 million in YTD 2017, representing an increase of \$15.4 million. This change is primarily driven by a \$0.9 million decrease in net income adjusted for non-cash items and a \$14.4 million decrease in the net change in non-cash working capital from (\$2.5 million) in YTD 2017 to (\$17.0 million) in YTD 2018.

Investing Activities. During YTD 2018, the Company used \$38.3 million of cash in investing activities, primarily due to \$37.7 million in capital expenditures that were used to fund expansion efforts at Peace Naturals, namely Building 4 and the Peace Naturals greenhouse.

Financing Activities. During YTD 2018, cash provided by financing activities was \$139.3 million, primarily due to \$136.6 million in net proceeds from the April 2018 Bought Deal and the January 2018 Bought Deal (as defined herein).

Capital Resources

Debt

In August 2017, we entered into a senior secured loan, to be funded by way of multiple advances, for up to \$40.0 million in committed capital (the “**Construction Loan**”) with Romspen Investment Corporation (“**Romspen**”). Each advance is subject to certain conditions, including, among other things, Romspen’s approval of construction progress. The Construction Loan is secured by a first ranking charge on the real estate of each of Peace Naturals and OGBC. OGBC, Hortican Inc. (“**Hortican**”), and the Company are also guarantors of the Construction Loan. Under the terms of the Construction Loan, Peace Naturals, OGBC, Hortican and the Company retain the ability to enter into equipment financing arrangements, and the Company retains the ability to raise capital by issuing common shares. Aggregate loan advances are limited to \$35.0 million until Romspen receives an appraisal value of the OGBC property of at least \$8.0 million. The Construction Loan bears a 12% annual interest rate and carries a two-year term, with a one-year extension option in favor of the Company subject to certain terms and conditions. The Construction Loan contains customary affirmative and negative covenants and events of default. As at June 30, 2018, we were in material compliance with all covenants contained in the Construction Loan. See note 14 “Construction loan payable” in the notes to the Interim Financial Statements for additional information.

As of June 30, 2018, \$6.3 million has been funded under the Construction Loan, resulting in at least an additional \$28.7 million of additional borrowings available to us under the loan subject to certain terms and conditions, plus an additional \$5.0 million in additional borrowings if the OGBC property appraisal value in excess of \$8.0 million is completed.

Contractual Obligations

The Company has the following contractual obligations relating to debt financing, equipment, vehicle and office leases.

(\$ in 000s)

	Payments Due by Period				
	Total	Less Than 1 Year	1-3 Years	4-5 Years	After 5 Years
Long-Term Debt	\$ 6,304	\$ —	\$ 6,304	\$ —	\$ —
Finance Lease Obligations	211	53	158	—	—
Operating Leases	447	44	300	103	—
Purchase Obligations	5,000	5,000	—	—	—
Total Contractual Obligations	11,962	5,097	6,762	103	—

Long term debt obligations relate to the outstanding balance under the Construction Loan due August 2019. Finance lease obligations relate to equipment leases maturing in June 2022. Operating lease obligations relate to office equipment and vehicle leases as well as the Company’s headquarters office space lease that terminates in February 2023. Purchase obligations relate to equipment purchase commitments associated with the construction of Building 4 at Peace Naturals.

Equity

The Company has historically funded operations and financed production capacity expansion primarily through the sale of equity securities. During YTD 2018, we have raised \$146.0 million in gross proceeds (not taking into account any commissions, fees or expenses) through two common share offerings:

- In January 2018, the Company closed a bought deal offering (the “**January 2018 Bought Deal**”) pursuant to which the Company sold a total of 5,257,143 common shares at a price of \$8.75 per common share for aggregate gross proceeds of approximately \$46.0 million. The bought deal was completed by way of a short form prospectus offering in Canada.
- In April 2018, the Company closed the April 2018 Bought Deal pursuant to which the Company sold a total of 10,420,000 common shares at a price of \$9.60 per common share for aggregate gross proceeds of approximately \$100.0 million. The common shares were offered in the U.S. pursuant to the Company’s effective registration statement on Form F-10 filed with the U.S. Securities and Exchange Commission (“**SEC**”) and in Canada by way of a short form prospectus offering.

Use of Proceeds

Below is a reconciliation of the manner in which the net proceeds from the April 2018 Bought Deal were used by the Company compared to the disclosure in the Company's final short form prospectus dated March 29, 2018 (the "**March 2018 Final Prospectus**").

Disclosure in the March 2018 Final Prospectus

\$10,000,000 for its proportionate share of capital expenditures relating to construction and operating expenses of Cronos Australia in connection with Phase I of Cronos Australia.

\$5,000,000 to purchase equipment for use in Cronos Israel's greenhouse and manufacturing facility for Phase I of Cronos Israel.

The remaining net proceeds for general working capital purposes, including working capital for the Company's international operations, and as capital on hand for potential new investment opportunities.

Use of Proceeds

The Company has advanced \$0.4 million of the proceeds in connection with the construction or operating expenses of Cronos Australia and expects to apply such remaining proceeds in 2018.

The Company has not yet applied any of the proceeds in connection with the equipment purchase for use in Cronos Israel. The \$5.0 million has been set aside for future equipment purchases for Phase I of Cronos Israel.

The Company has not applied any remaining net proceeds to date.

Below is a reconciliation of the manner in which the net proceeds from the January 2018 Bought Deal were used by the Company compared to the disclosure in the Company's final short form prospectus dated January 18, 2018 (the "**January 2018 Final Prospectus**").

Disclosure in the January 2018 Final Prospectus

\$5,000,000 for research and development ("**R&D**") initiatives, including cannabinoid production research and clinical trials.

\$30,000,000 for expanding production capacity, including: (i) the continued expansion of production capacity at Building 4 and the Peace Naturals greenhouse; and (ii) the construction of Cronos Israel's production facilities and general working capital for Cronos Israel operations.

The remaining net proceeds for general working capital purposes which may include establishing new international distribution channels in jurisdictions where there is a federal legal framework for medical cannabis and the associated costs of compliance with applicable regulatory requirements.

Use of Proceeds

The Company applied approximately \$0.5 million of the net proceeds of the January 2018 Bought Deal to R&D initiatives, including cannabinoid production research.

The remaining approximately \$4.5 million allocated for R&D initiatives in the January 2018 Final Prospectus has been set aside for ongoing research in product formulation, clinical trials, and cannabinoid production research and are expected to be applied in 2018.

The Company applied approximately \$28.0 million of the net proceeds of the January 2018 Bought Deal for expanding production capacity, including \$26.5 million on general construction costs and deposits on equipment for the continued construction of Building 4 and the Peace Naturals greenhouse. An additional \$2.0 million of the net proceeds were applied to clearing the land, deposits on the greenhouse and equipment relating to Cronos Israel's production facilities and \$0.1 million on general working capital for Cronos Israel operations.

The Company applied approximately \$1.8 million of the net proceeds of the January 2018 Bought Deal to general working capital.

The remaining approximately \$6.3 million (which does not account for the Company's expenses in relation to the January 2018 Bought Deal) has been set aside for continued general working capital purposes.

Below is a reconciliation of the manner in which the net proceeds from the bought deal offering of common shares in November 2017 (“**November 2017 Bought Deal**”) were used by the Company compared to the disclosure in the Company’s final short form prospectus dated November 3, 2017 (the “**November 2017 Final Prospectus**”).

Disclosure in the November 2017 Final Prospectus	Use of Proceeds
\$7,000,000 for expanding production at Peace Naturals. This includes general construction costs, the contractor’s management fees, labor costs, material (e.g. structural steel, roofing material, and paneling) and equipment (e.g. irrigation, generators) for the continued construction of Building 4 and Peace Naturals’ greenhouse.	<p>The Company applied approximately \$10.1 million of the net proceeds of the November 2017 Bought Deal plus an additional \$0.6 million from operations, for a total of \$10.7 million to general construction costs and deposits on equipment for the continued construction of Building 4 and Peace Naturals’ greenhouse.</p> <p>Such amount represents the \$7.0 million allocated for such use in the November 2017 Final Prospectus, plus an additional amount equal to approximately \$3.1 million from the net proceeds allocated to general working capital purposes in the November 2017 Final Prospectus (including approximately \$2.1 million of the net proceeds from the exercise of the November 2017 Bought Deal over-allotment option) and an additional \$0.6 million from operations.</p>
\$3,000,000 for R&D initiatives, including product formulation and the purchase of associated production equipment.	<p>The Company applied approximately \$0.5 million for R&D initiatives associated with plant and process productivity.</p> <p>The remaining approximately \$2.5 million allocated for R&D initiatives in the November 2017 Final Prospectus has been set aside for ongoing research in product formulation, clinical trials, and plant process productivity and are expected to be applied in 2018.</p>
\$3,000,000 for investment in the development of infrastructure for the anticipated distribution of cannabis pursuant to the Cannabis Act, including the development of branding and market positioning.	<p>The Company applied approximately \$1.0 million in branding and new packaging, and consulting support for the development of infrastructure for distribution of cannabis pursuant to the Cannabis Act.</p> <p>The remaining approximately \$2.0 million, allocated for investment in the development of infrastructure for the anticipated distribution of cannabis pursuant to the Cannabis Act, has been set aside for costs associated with obtaining distribution licenses in various provinces, hiring additional sales staff in connection with such anticipated expanded distribution and additional product offerings anticipated with recreational use in Canada (e.g., edibles).</p>
The remaining net proceeds for general working capital purposes which may include establishing new international distribution channels in jurisdictions where there is a legal framework for medical cannabis and the associated costs of compliance with Health Canada and other regulatory requirements.	<p>The Company reallocated approximately \$3.1 million (which does not account for the Company’s expenses in relation to the November 2017 Bought Deal) originally allocated for general working capital purposes in the November 2017 Final Prospectus (including approximately \$2.1 million of the net proceeds from the exercise of the November 2017 Bought Deal over-allotment option), plus an additional \$0.6 million from operations, for a total reallocated amount of \$3.7 million to general construction costs and deposits on equipment for the continued construction of Building 4 and Peace Naturals’ greenhouse. As a result, no net proceeds from the November 2017 Bought Deal were allocated to general working capital purposes.</p>

Financial Condition

We currently anticipate that our cash flow from operations, cash and additional borrowings available under the Construction Loan will be sufficient to satisfy our operational cash needs through at least the next 12 months.

However, any projections of future cash needs and cash flows are subject to substantial uncertainty. Our ability to fund operating expenses and capital expenditures will depend on, among other things, our future operating performance, which will be affected by general economic, financial and other factors, including factors beyond our control.

The Company, from time to time, may need or want to raise additional capital to strengthen its financial position, facilitate expansion, pursue strategic acquisitions and investments, and take advantage of business opportunities as they arise. Although we have been successful in the past in obtaining financing, there can be no assurance that such additional capital will be available in amounts or on terms acceptable to us, if at all. If we cannot raise additional funds when we need or want them, our operations and prospects could be negatively affected. See “Risks and Uncertainties” in this MD&A for additional information.

SHARE INFORMATION

The issued and outstanding common shares, along with shares potentially issuable, are as follows as of the date indicated below.

<i>(Actual shares)</i>	As at August 13, 2018
Issued and Outstanding Shares	
Common Shares	177,147,970
Total Issued and Outstanding Shares	177,147,970
Potentially Issuable Shares	
Stock Options	12,871,900
Warrants	25,457,625
Total Potentially Issuable Shares	38,329,525
Total Outstanding and Potentially Issuable Shares	215,477,495

LEGAL PROCEEDINGS

As of the date of this MD&A, we are subject to four ongoing claims for damages. See note 20 “Commitments and contingencies” to the Interim Financial Statements for further discussions on our legal proceedings. We believe that all allegations in each proceeding are without merit and plan to vigorously defend ourselves; accordingly, no provision for loss has been recognized.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this MD&A, we have no off-balance sheet arrangements.

FINANCIAL INSTRUMENTS

As of the date of this MD&A, we have no financial instruments or other instruments, such as hedging instruments.

TRANSACTIONS BETWEEN RELATED PARTIES

The Company has engaged in transactions with related parties as follows:

(\$ in 000s)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Key Management Compensation				
Short-Term Employee Benefits, Including Salaries and Fees	\$ 110	\$ 106	\$ 219	\$ 212
Professional Fees	58	—	116	71
Stock-Based Payments	356	161	695	228
Total Key Management Compensation	524	267	1,030	511

Key management personnel are persons responsible for planning, directing and controlling activities of an entity, and include executives and non-executive directors. As at June 30, 2018, there were no balances payable to members of key management (December 31, 2017 - \$Nil).

NEW ACCOUNTING PRONOUNCEMENTS

The IASB has not issued any new standards, amendments to standards, or interpretations that have impacted the Company during Q2 2018.

Adoption of New Accounting Pronouncements

Our adoption of previously issued new standards, amendments to standards, and interpretations are set forth below.

Amendments to IFRS 2 Share-based Payments

The amendments to IFRS 2 clarify how to account for certain types of share-based payment transactions. The amendments provide requirements on the accounting for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments, share-based payment transactions with a net settlement feature for withholding tax obligations, and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The effective date of these amendments was January 1, 2018. The Company has adopted these amendments as of the effective date and has assessed no significant changes as a result of the adoption of these amendments on the current period.

IFRS 9 Financial Instruments

IFRS 9 addresses classification and measurement of financial assets and replaces the multiple category and measurement models in IAS 39 for debt instruments with a new mixed measurement model having only three categories: amortized cost, fair value through other comprehensive income, and fair value through profit or loss. IFRS 9 also replaces the models for measuring equity instruments and such instruments are either recognized at fair value through profit or loss or at fair value through other comprehensive income. The effective date of this standard was January 1, 2018. The Company has adopted this new standard as of its effective date on a retrospective basis with the exception of financial assets that were derecognized at the date of initial application, January 1, 2018. The 2017 comparatives were not restated. As a result of the new classification model and measurement requirements under IFRS 9, the Company has elected to classify the available-for-sale investments as fair value through other comprehensive income investments. Under this classification, there is no recycling of gains or losses from accumulated other comprehensive income to profit or loss. Due to the adoption of IFRS 9, during the three and six months ended June 30, 2018, a net gain (loss) of approximately (\$0.2 million) and \$0.3 million respectively on the disposal of investments classified as fair value through other comprehensive income was recorded in other comprehensive income rather than profit or loss during the period.

IFRS 15 Revenue from Contracts with Customers

IFRS 15 was issued by the IASB in May 2014 and specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. IFRS 15 became effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. The Company has adopted this new standard as of its effective date using the full retrospective method of adoption, and has assessed no significant changes as a result of the adoption of this new standard on the current period.

Under IFRS 15, the revenue recognition model has changed from one based on the transfer of risks and rewards of ownership to the transfer of control. The Company's contracts with customers for the sales of dried cannabis and cannabis oil include one performance obligation, a promise in a contract with a customer to transfer a good or service. As the transfer of risks and rewards generally coincides with the transfer of control at a point in time, upon shipment or delivery, depending on the contract, the timing and amount of revenue considering discounts, rebates, and variable consideration, recognized from this principal revenue stream has not changed as a result of the adoption of this new standard.

ESTIMATES AND CRITICAL JUDGMENTS BY MANAGEMENT

The preparation of these unaudited condensed interim consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are reviewed periodically and adjustments are made as appropriate in the year they become known. Items for which actual results may differ materially from these estimates are described in the following section.

Warrants and options

Warrants and options are initially valued at fair value, based on the application of the Black-Scholes option pricing model. This pricing model requires management to make various assumptions and estimates which are susceptible to uncertainty, including the volatility of the share price, expected dividend yield, expected term of the warrant or option and expected risk-free interest rate.

Useful lives and impairment of long-lived assets

Long-lived assets are defined as property, plant and equipment and intangible assets with finite lives. Depreciation and amortization are dependent upon estimates of useful lives and impairment is dependent upon estimates of recoverable amounts. These are determined through the exercise of judgment, and are dependent upon estimates that take into account factors such as economic and market conditions, frequency of use, anticipated changes in laws, and technological improvements.

Impairment of cash-generating units and goodwill

The impairment test for cash generating units ("CGUs") to which goodwill is allocated is based on the value in use of the CGU, determined in accordance with the expected cash flow approach. The calculation is based on assumptions used to estimate future cash flows, the cash flow growth rate and the discount rate.

Fair value of privately held financial assets classified as fair value through other comprehensive income

The Company's management considers specific information about the investee companies, trends in general market conditions, and the share performance of similar publicly traded companies when valuing the Company's privately held investments.

Management considers the following factors to indicate a change in the fair value, or impairment of, a privately held investment, and may adjust the value if:

- there has been significant subsequent equity financing provided by outside investors at a value which differs from the current

- recorded value of the investee company, in which case the fair value of the investment is adjusted to equal the value at which that financing took place;
- there have been significant corporate, political, legal, or operating events affecting the investee company such that management believes they will materially impact the investee company's prospects and therefore its fair value. In these circumstances, the adjustment to fair value of the investment will be based on management's judgment;
- the investee company is placed into receivership or bankruptcy;
- based on financial information received from the investee company, it is evident that the investee company is unlikely to be able to continue as a going concern;
- receipt or denial by the investee company of medical marijuana licenses from Health Canada, which allow the investee company to initiate or continue operations; and
- management changes by the investee company that the Company's management believes will have an impact on the investee company's ability to achieve its objectives and build value for shareholders.

Income taxes

Income taxes and tax exposures recognized in the unaudited condensed interim consolidated financial statements reflect management's best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to take into account certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

Biological assets and inventory

Biological assets, consisting of cannabis plants, are measured at fair value less costs to sell. At the point of harvest, the biological assets are transferred to inventory at fair value less costs to sell. As a result, critical estimates related to the valuation of biological assets are also applicable to inventory.

Determining the fair value less costs to sell requires the Company to make assumptions about the expected future yield from the cannabis plants, the value associated with each stage of the plants' growth cycle, estimated selling price, costs to convert harvested cannabis into finished goods, and costs to sell. The Company's estimates are, by their nature, subject to change.

DISCLOSURE CONTROLS AND INTERNAL CONTROL OVER FINANCIAL REPORTING

In accordance with National Instrument 52-109 – Certification of Disclosure in Issuers' Annual and Interim Filings, management is responsible for establishing and maintaining disclosure controls and procedures ("DC&P") and internal control over financial reporting ("ICFR"). Management has designed DC&P and ICFR based on the 2013 Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

The Company's disclosure controls and procedures are designed to provide reasonable assurance that material information relating to the Company is made known to senior management, including the Chief Executive Officer ("CEO") and the Chief Financial Officer ("CFO") and information required to be disclosed by the Company is recorded, processed, summarized and reported within the time periods specified in securities legislation. ICFR is designed, under the supervision of the CEO and CFO, to provide reasonable assurance regarding the reliability of the Company's financial reporting and the preparation of its financial statements in accordance with IFRS.

As at June 30, 2018, the CEO and CFO concluded that the designs of DC&P and ICFR were adequate and provided such reasonable assurances.

The Company has devoted significant resources and time to design and implement its current ICFR program. The Company continues to engage third party resources specialized in ICFR implementations to enhance its current controls and the associated processes and systems. Additionally, the Company has provided significant human resources to these efforts, including hiring new employees to assist in ICFR activities and training of key process owners. Management has consistently embraced the importance of maintaining a robust ICFR program and is committed to enhancing the current system through continuous improvement and review.

Changes in Internal Control Over Financial Reporting

In the ordinary course of business, we review our ICFR system and make changes to our applications and processes to improve such controls and increase efficiency, while ensuring that we maintain an adequate internal control environment. During Q2 2018, there were

no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our ability to certify the design of our internal control over financial reporting.

Limitations of Controls and Procedures

Because of its inherent limitations, any DC&P and ICFR system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system is meeting the Company's objectives in providing reliable financial reporting information in accordance with IFRS. These inherent limitations include, but are not limited to, human error and circumvention of controls and as such, there can be no assurance that the controls will prevent or detect all misstatements due to error or fraud, if any. Additionally, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

RISKS AND UNCERTAINTIES

We are subject to various risks that could have a material impact on us, our financial performance, condition and outlook. These risks could cause actual results to differ materially from those expressed or implied in Forward-Looking Statements included in this MD&A, our financial statements and our other reports and documents. These risks include but are not limited to, the following risks:

- We are reliant on our licenses for our ability to grow, store and sell medical cannabis and other products derived therefrom and such licenses are subject to ongoing compliance, reporting and renewal requirements, including significant upcoming changes under the new Cannabis Act.
- Our ability to continue to grow, process, store and sell medical cannabis and participate in the Canadian recreational cannabis market is dependent on a successful transition of our current licenses from the CDSA to the Cannabis Act, and this process is still uncertain.
- We operate in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business.
- Licensed Producers, including our Licensed Producers, are constrained by law in our ability to package, advertise and market our products.
- The laws, regulations and guidelines generally applicable to the cannabis industry domestically are changing and may change in ways currently unforeseen by us.
- Changes in the regulations governing medical cannabis outside of Canada may adversely impact our business.
- The complete legislative framework pertaining to the Canadian recreational cannabis market is still uncertain and new guidelines are expected and may provide interpretations or requirements unforeseen by us.
- Future clinical research studies on the effects of medical cannabis may lead to conclusions that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis.
- Our expansion into jurisdictions outside of Canada is subject to risks.
- We may not receive the equity interests in Cronos Israel and may not realize the expected benefits of Cronos Israel.
- Investments and joint ventures outside of Canada are subject to the risks normally associated with any conduct of business in foreign countries, including varying degrees of political, legal and economic risk.
- If we choose to engage in research and development activities outside of Canada, controlled substance legislation may restrict or limit our ability to research, manufacture and develop a commercial market for our products.
- Our use of joint ventures may expose us to risks associated with jointly owned investments.
- There can be no assurance that our current and future strategic alliances or expansions of scope of existing relationships will have a beneficial impact on our business, financial condition and results of operations.
- We and certain of our subsidiaries have limited operating history and therefore we are subject to many of the risks common to early-stage enterprises.
- Our existing facilities in Canada are integral to our operations and any adverse changes or developments affecting any facility may impact our business, financial condition and results of operations.
- We may not successfully execute our production capacity expansion strategy.
- The cannabis industry and markets are relatively new in Canada and in other jurisdictions, and this industry and market may not continue to exist or grow as anticipated or we may ultimately be unable to succeed in this industry and market.
- We are dependent on our senior management.
- We may be subject to product liability claims.
- Our products may be subject to recalls.

- We may be unable to attract or retain skilled labor and personnel with experience in the cannabis sector, and may be unable to attract, develop and retain additional employees required for our operations and future developments.
- We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer perception.
- We may not be able to successfully develop new products or find a market for their sale.
- The technologies, process and formulations we use may face competition or become obsolete.
- Clinical trials of cannabis-based medical products and treatments are novel terrain with very limited or non-existing clinical trials history; we face a significant risk that any trials will not result in commercially viable products and treatments.
- We may fail to retain existing patients as clients or acquire new patients as clients.
- We may not be able to achieve or maintain profitability and may continue to incur losses in the future.
- We may not be able to secure adequate or reliable sources of funding required to operate our business.
- We must rely largely on our own market research to forecast sales and market demand which may not materialize.
- We may experience breaches of security at our facilities or in respect of electronic documents and data storage and may face risks related to breaches of applicable privacy laws.
- If we are not able to comply with all safety, health and environmental regulations applicable to our operations and industry, we may be held liable for any breaches thereof.
- We may become involved in regulatory or agency proceedings, investigations and audits.
- We may be subject to or prosecute litigation in the ordinary course of business.
- We may not be able to successfully manage our growth.
- The expected growth in the number of patients using the Company's medical cannabis.
- The Company's international activities and joint venture interests, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact.
- We may compete for market share with other companies, both domestically and internationally, which may have longer operating histories and more financial resources, manufacturing and marketing experience than us.
- Third parties with whom we do business may perceive themselves as being exposed to reputational risk as a result of their relationship with us and may, as a result, refuse to do business with us.
- Our cannabis cultivation operations are subject to risks inherent in an agricultural business.
- Our cannabis cultivation operations are vulnerable to rising energy costs and dependent upon key inputs.
- We are vulnerable to third party transportation risks.
- We may become subject to liability arising from any fraudulent or illegal activity by our employees, contractors and consultants.
- We will seek to maintain adequate insurance coverage in respect of the risks faced by us, however, insurance premiums for such insurance may not continue to be commercially justifiable and there may be coverage limitations and other exclusions which may not be sufficient to cover potential liabilities faced by us.
- Our debt imposes limitations on the type of transactions or financial arrangements in which we may engage.
- We are subject to certain restrictions of the TSX which may constrain our ability to expand our business internationally.
- Failure to establish and maintain effective internal controls over financial reporting may result in us not being able to accurately report our financial results, which could result in the loss of investor confidence and adversely affect the market price of our common shares.
- We may be subject to risks related to the protection and enforcement of our intellectual property rights, and may become subject to allegations that we are in violation of intellectual property rights of third parties.
- Conflicts of interest may arise between us and our directors and officers.
- Tax and accounting requirements may change in ways that are unforeseen to us and we may face difficulty or be unable to implement or comply with any such changes.
- Our financial performance is subject to risks of foreign exchange rate fluctuation which could result in foreign exchange losses.
- The inability for counterparties and customers to meet their financial obligations to us may result in financial losses.
- Natural disasters, unusual weather, pandemic outbreaks, boycotts and geo-political events or acts of terrorism could adversely affect our operations and financial results.

A more detailed description of the various risks associated with the Company can be found under the heading "Risk Factors" in our latest AIF.

ADDITIONAL INFORMATION

Our Canadian filings, including our latest AIF, are available on the System for Electronic Document Analysis and Retrieval at www.sedar.com. Our reports and other information filed with the SEC are available on the SEC's Electronic Document Gathering and Retrieval System at www.sec.gov.

FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE

I, Michael Gorenstein, Chief Executive Officer and President of Cronos Group Inc., certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cronos Group Inc. (the “issuer”) for the interim period ended June 30, 2018.

2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.

5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

- (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
 - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
 - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is *Internal Control – Integrated Framework (2013)* (“COSO Framework”) published by the Committee of Sponsoring Organizations of the Treadway Commission.

5.2 **ICFR – material weakness relating to design:** N/A.

5.3 **Limitation on scope of design:** N/A.

6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on April 1, 2018 and ended on June 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

Date: August 14, 2018.

 “Michael Gorenstein”
 Michael Gorenstein
 Chief Executive Officer and President

FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE

I, William Hilson, Chief Financial Officer of Cronos Group Inc., certify the following:

1. **Review:** I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Cronos Group Inc. (the “issuer”) for the interim period ended June 30, 2018.

2. **No misrepresentations:** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. **Fair presentation:** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. **Responsibility:** The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, for the issuer.

5. **Design:** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

- (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
 - (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
 - (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

5.1 **Control framework:** The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is *Internal Control – Integrated Framework (2013)* (“COSO Framework”) published by the Committee of Sponsoring Organizations of the Treadway Commission.

5.2 **ICFR – material weakness relating to design:** N/A.

5.3 **Limitation on scope of design:** N/A.

6. **Reporting changes in ICFR:** The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on April 1, 2018 and ended on June 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

Date: August 14, 2018.

“William Hilson”

William Hilson
Chief Financial Officer